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Summary 
 
Comprehensive integration site analysis for monitoring the clonal dynamics in clinical gene 
therapy has revealed that the insertion of the therapeutic retroviral vector (RV) can 
deregulate and even substantially activate neighboring genes leading to selection advantage 
and clonal outgrowth. Strikingly, 7 out of 10 Wiskott Aldrich Syndrome (WAS) gene therapy 
patients developed acute leukemia driven by gene corrected cell clones aberrantly 
expressing LMO2, MDS1 or MN1. This indicates that RV-mediated activation of adjacent 
regions cannot only influence the fate of hematopoietic stem cells but also cause clonal 
dominance up to leukemia. To identify novel regulators of benign hematopoiesis we 
established a systematic selection strategy using the total genomic integration site dataset 
of normal and highly polyclonal clinical blood and bone marrow samples.  
In this thesis, the unique integration site (IS) dataset within a cohort of 10 WAS gene therapy 
patients was systematically analyzed to select for candidate genes involved in the regulation 
of hematopoiesis. Initially, a total of 12.887 unique IS in vicinity of 3.267 genes were 
identified. Next, we selected all genes with at least 10 different IS within a 200 kb window 
around the gene (n=588). To enrich for genes with increased probability of transcriptional 
activation we then chose those genes with at least 10 IS within a 50kb window around the 
transcriptional start site (n=424). After stringent exclusion of all genes located within gene 
clusters 32 candidate genes were identified. To evaluate the hematopoietic activity of gene 
corrected cell clones, their contribution to blood cell formation within four years post gene 
therapy was monitored. We observed that these clones were detectable 15 to 93 times in a 
total of 102 individually analyzed patient samples, demonstrating long term activity of these 
hematopoietic stem cell clones. Interestingly, 20 out of the 32 highest ranked genes such as 
EVI1, CCND2 and LMO2 are known hematopoietic key regulators, strongly validating our 
selection strategy. After identification of 12 novel hematopoietic regulatory candidate 
genes, the top five ranked genes, ZNF217, LRRC33, PLCB4, EVL and IRF2BPL were chosen for 
further functional analysis in murine hematopoietic primary cells.  
To evaluate the endogenous expression of candidate genes in murine hematopoietic stem 
and progenitor cells global transcriptome datasets from purified populations were 
evaluated. We observed that all five selected candidate genes were expressed in at least one 
out of the five analyzed hematopoietic stem and progenitor cell populations which may 
point to an important role in the respective cell fraction. In order to validate our selection 
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strategy and to further investigate whether the chosen candidate genes play roles in 
hematopoiesis, we performed various in vitro and in vivo assays. We tested the effect of the 
selected candidate genes on proliferation, differentiation, and cytokine independency as 
well as for their influence on long term multilineage reconstitution and self-renewal after 
murine bone marrow transplantation.  
The first candidate gene, ZNF217, is a zinc finger protein known as a transcription factor. To 
analyze the impact of ZNF217 on transcriptional activity, global gene expression profiling in 
hematopoietic cells was performed. We observed that 337 out of 422 genes were 
significantly downregulated and that they are mainly involved in cellular movement 
indicating that ZNF217 plays a role in hematopoietic cell migration. Since ZNF217 is known as 
a proto-oncogene in breast and ovarian carcinoma we evaluated its effect on growth factor 
independency of hematopoietic cells. Interleukin 3 (IL3)-dependent cells overexpressing 
ZNF217 acquired the capacity to survive and form colonies in the absence of IL3 suggesting a 
transforming role for ZNF217 in hematopoietic cells.  
The second candidate LRRC33 resembles the protein structure of Toll-like receptor (TLR) 
proteins which are involved in innate immunity. The overexpression of LRRC33 and TLR4 
decreased the activity of NF-κB in vitro when stimulated with bacterial lipopolysaccharide. 
This may point to an inhibitory role of LRRC33 in NF-kB signaling, an important pathway for 
maintaining stem cell integrity. Transplanted LRRC33-overexpressing LSK (Lin-Sca-1+cKit+) 
cells gave rise to a 1.3-6.7-fold lower ratio of T-cells and in contrast a 1.1-7.2-fold higher 
amount of donor derived macrophages in secondary recipients compared to control mice. 
To study the function of the third candidate gene on hematopoiesis constitutive PLCB4 
knockout mice were obtained. This phospholipase has been shown to be important for brain 
development but has not been linked to hematopoiesis so far. Preliminary results indicate 
that PLCB4 deficient mice have a reduced LSK cell fraction compared to age matched 
littermates within the first 18 days after birth.  
These results demonstrate that clinical integration site datasets can be used to identify 
regulatory genes of hematopoiesis. Here, we identified ZNF217 as a driver of hematopoietic 
transformation applying the established selection strategy. In total, we could show that four 
out of five candidate genes play a role in hematopoiesis and they will be further evaluated 
for their stem cell regulatory potential. Systematic identification of novel regulatory genes in 
meta-datasets derived from a larger number of gene therapy studies and subsequent 
validation in vitro and in vivo will allow to gain new insights into the biology of post-
embryonic hematopoiesis. 
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Zusammenfassung 
Umfassende Integrationsstellen (IS)-analysen zur Beobachtung der klonalen 
Zusammensetzung in Gentherapie-Studien haben gezeigt, dass die Insertion des 
therapeutischen retroviralen Vektors  (RV) benachbarte Gene durch transkriptionelle 
Aktivierung deregulieren kann. Dies kann zu einem Selektionsvorteil und klonalem 
Auswachsen bestimmter Zellklone führen. Auffallenderweise haben 7 von 10 Gentherapie-
Patienten mit Wiskott-Aldrich Syndrom eine akute Leukämie entwickelt, die von Gen-
korrigierten Zellklonen mit aktivierenden Vektor-Insertionen vor den Genen LMO2, MDS1 
oder MN1 getrieben wurden. Dies weist darauf hin, dass die RV initiierte Aktivierung 
benachbarter Genregionen nicht nur das Schicksal hämatopoetischer Stammzellen 
beeinflussen, sondern auch klonale Dominanz bis hin zur Leukämie-Entstehung zur Folge 
haben kann. Eine systematische Analyse von klinischen IS Datensätzen und die 
Klassifizierung von genomischen Anhäufungen dieser IS sollte zur Identifizierung 
bedeutender hämatopoetischer Gene führen. Deshalb wurde in der vorliegenden Arbeit 
mittels klinischer Daten von RV markierter polyklonaler Blutbildung eine Selektionsstrategie 
entwickelt, um bisher unbekannte Stammzellregulatoren zu ermitteln. 
Um Kandidaten-Gene zu identifizieren, wurde der einzigartige klinische IS Datensatz von 
insgesamt 12887 spezifischen IS von einer Kohorte von 10 Patienten analysiert. In der Nähe 
dieser individuellen Insertionen  wurden  3267 Protein-kodierende Gene ermittelt. Im 
nachfolgenden Schritt, wurden Gene gewählt, welche mindestens 10 unterschiedliche IS in 
einem 200 kb Fenster um ihre Loki aufwiesen (n=588). Um die Wahrscheinlichkeit zu 
erhöhen, dass die umliegenden Gene durch die Vektorinsertionen transkriptionell aktiviert 
wurden, wurden diese mit mindestens 10 IS in einem Bereich von 50 kb um den 
Transkriptionsstart gewählt (n=424). Nach stringentem Ausschluss von Genen, welche auf 
genomischer Ebene nicht einzeln, sondern in Gruppen lokalisiert vorliegen, wurden 32 
eindeutig zuordenbare Kandidaten identifiziert. Um die hämatopoetische Aktivität dieser 
spezifischen Gen-korrigierten Klone zu untersuchen, wurde deren Beitrag zur humanen 
Blutbildung während einem Zeitraum von vier Jahren nach Gentherapie überprüft. Dabei 
haben wir festgestellt, dass diese Zellklone in 15 bis 93 Fällen von 102 individuell 
analysierten Blutproben detektiert werden konnten, was auf eine kontinuierliche 
hämatopoetische Aktivität dieser Klone hindeutet. Interessanterweise sind 20 der 32 
Kandidaten-Gene mit den namhaften Vertretern LMO2, EVI1 und CCND2 bereits bekannte 
hämatopoetische Regulatoren, was unsere Auswahlstrategie immens stützt und validiert. 
Nach Identifizierung von 12 neuen hämatopoetischen Kandidaten-Genen wurden die fünf 
höchst Gelisteten zur detailierten funktionalen Untersuchung in murinen hämatopoetischen 
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Primärzellen ausgewählt. Um die endogenen Expressionslevel dieser Kandidaten in 
definierten hämatopoetischen Stamm- und Progenitorzell-Populationen zu bewerten, 
wurden globale Transkriptom-Daten ausgewertet. Alle fünf Kandidaten wurden in 
mindestens einer der fünf aufgereinigten Zellpopulationen exprimiert, was auf eine wichtige 
Rolle in der entsprechenden Fraktion hindeuten könnte. Um umfassender zu untersuchen, 
ob die ausgewählten Kandidaten-Gene Stammzell-regulatorisches Potential besitzen, 
wurden verschiedene in vitro und in vivo Experimente verwendet. Es wurde einerseits der 
Einfluss der Kandidaten auf Proliferation, Differenzierungsfähigkeit und Zytokin-
Abhängigkeit, andererseits deren Auswirkung auf die Langzeitblutbildung und 
Selbsterneuerungsfähigkeit im lebenden Organismus untersucht. Das erste Kandidatengen 
ist ein Zinkfingerprotein, ZNF217, und als Transkriptionsfaktor bekannt. Um das Potential als 
transkriptioneller Regulator in hämatopoetischen Zellen zu untersuchen, wurden nach 
dessen Überexpression globale Genexpressionsanalysen durchgeführt. 337 von 422 
deregulierten Genen waren signifikant herunter-reguliert und der Großteil kann in den 
Prozess der zellulären Bewegung eingruppiert werden, was auf eine Rolle von ZNF217 bei 
der Migration von  hämatopoetischen Zellen hindeuten könnte. Da ZNF217 in Brust- und 
Ovarialkarzinomen als Proto-Onkogen beschrieben wurde, wurde sein Einfluss auf die 
Wachstumsfaktorunabhängigkeit in hämatopoetischen Zellen untersucht. Die 
Überexpression von ZNF217 führte unter Mangel von Interleukin 3 (IL3) zum Überleben und 
Wachstum von Zytokin-unabhängigen Kolonien, was auf eine transformierende Eigenschaft 
von ZNF217 in hämatopoetischen Zellen schließen lässt. Der zweite Kandidat, LRRC33 ähnelt 
in seiner Proteinstruktur Toll-like-Rezeptoren (TLR), welche eine Rolle in der angeborenen 
Immunität spielen. Es konnte  gezeigt werden, dass nach Stimulierung mit bakteriellem 
Lipopolysaccharid in vitro die Überexpression von LRRC33 und TLR4 zu einer reduzierten 
Aktivität von NFκB führt. Dies deutet auf einen inhibitorischen Einfluss von LRRC33 auf das 
NFκB Signaling hin, was ein wichtiger Signalweg zur Erhaltung hämatopoetischer 
Stammzellintegrität darstellt. Die Transplantation von LRRC33 exprimierenden LSK (lin-
Sca1+ckit+) Zellen ergab im Vergleich zu Kontrollmäusen eine 1,3-6,7 fach geringere Menge 
an T-Zellen und einen 1,1-7,2 fach höheren Anteil an Makrophagen in sekundär 
transplantierten Rezipienten. Um die Funktion des dritten Kandidatengens, PLCB4 zu 
untersuchen, wurden Knockout-Mäuse eingesetzt. Es wurde bereits gezeigt, dass diese 
Phospholipase eine große Bedeutung während der Gehirnentwicklung besitzt, jedoch ist 
bisher noch kein Zusammenhang zur Blutentwicklung beschrieben worden. Erste Ergebnisse 
deuten darauf hin, dass PLCB4 defiziente Mäuse einen im Vergleich zu altersgemäßen 
Wildtyp-Wurfgeschwistern geringeren Anteil an hämatopoetischen LSK Zellen während den 
ersten 18 Tagen nach Geburt aufweisen. 
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Die Ergebnisse der hier vorliegenden Arbeit zeigen, dass klinische Integrationsstellen-
Datensätze verwendet werden können, um bisher unbekannte Stamzell-regulatorische Gene 
der Blutbildung zu identifizieren. Durch die Anwendung der hiermit entwickelten 
Selektionsstrategie konnte ZNF217 als Faktor hämatopoetischer Transformierung ermittelt 
werden. Zusammenfassend kann gesagt werden, dass vier von fünf ausgewählten 
Kandidaten eine Rolle während der Blutzellentwicklung spielen und weiterführende 
Untersuchungen das Stammzell-regulatorische Potential auf molekularer Ebene erfassen 
werden. Die systematische Identifizierung bisher unbekannter Stammzell-regulatorischer 
Gene mittels übergreifender Datensätze einer größeren Anzahl von Gentherapiestudien 
sowie deren schrittweise Validierung in in vitro und in vivo Ansätzen werden dazu beitragen, 
neue Einblicke in die Biologie adulter Hämatopoese zu gewinnen. 
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1 Introduction 
 
1.1 Hematopoiesis and hematopoietic stem cells 
Hematopoietic stem and progenitor cells (HSC and HPC) normally reside in the BM and 
represent about 0.01% of nucleated marrow cells [1]. These cells make a heterogeneous 
population in various aspects such as their degree of self-renewal, differentiation [2] and life 
span [3]. Since most mature blood stem cells have a limited life span, the ability of HSC to 
preserve themselves by self-renewal is critical [4]. Through hematopoietic differentiation, 
these cells lose their multipotency and increasingly become mature. HPC are able to give rise 
to large numbers of both myeloid (e.g. macrophages, granulocytes, erythrocytes, and 
megakaryocytes or platelets) and lymphoid lineages (e.g. T-cells and B-cells) [1, 5]. 
Hierarchical relationships exist among HSC, their progenies, and mature blood cells. In 
hierarchical differentiation models, multipotent HSC with self-renewal ability [16-18]; 
initially give rise to multipotent progenitors (MPP). MPP give rise to lymphoid-primed 
multipotent progenitors (LMPP) [6]. MPP and LMPP are considered as multipotent 
progenitor cells with limited or no self-renewal activity, which allows only short-term (up to 
8 weeks) multilineage repopulation. These multipotent progenitors generate lineage-
committed progenitors such as common myeloid progenitors (CMP)[7] which generate 
granulocyte-macrophage progenitors (GMP)[8], common lymphoid progenitors (CLP) [9], or 
megakaryocyte-erythroid progenitors (MEP), with loss of self-renewal ability [10] (Figure 1). 
Current models accept that HSC self-renewal capability is associated with multipotency and 
that HSC lose differentiation potential in the process of blood maturation. According to the 
present ‘‘classical’’ model, hierarchical differentiation proceeds with the first lineage 
commitment at the MPP stage, giving rise to all mature blood lineages. Several recent 
studies have questioned this scheme of lineage commitment largely because LMPPs with 
both neutrophil-monocyte and lymphoid potentials, but little or no megakaryocyte-erythroid 
potential (MkE), have been detected [3, 11] suggesting that an alternative MkE 
differentiation pathway may exist [10, 12]. 
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Figure 1: Model of the hematopoietic developmental hierarchy. HSC, hematopoietic stem cell; MPP, 
multipotent progenitor; LSK, Lineage- Sca-1+ cKit+ cells; CLP, common lymphoid progenitor; CMP, common 
myeloid progenitor; GMP, granulocyte-monocyte progenitor; MEP, megakaryocyte-erythroid progenitors. 
 
1.1.1 Hematopoietic stem cell heterogeneity  
The fact that a single HSC can generate millions of mature blood cells gave the first evidence 
to use clonal analyses for HSC detection [5, 13]. Fifty years ago the first HSC were defined as 
colony forming units spleen (CFU-S) since they were able to form visible colonies in spleen in 
a 1-2 week period, however they were found to contain very few longer-term hematopoietic 
repopulating cells [14-16]. CFU-S colonies contained cells which were able to generate 
secondary spleen colonies, and could reconstitute lethally irradiated mice [5, 13, 17]. 
 
A significant observation from the CFU-S study was the highly variable types of daughter 
cells generated in transplant experiments [17, 18]. This finding was later supported by in 
vitro analyses of multilineage colonies, where external stimuli could be kept the same [19, 
20], and later strengthened by retroviral vectors (RV) used to mark cells which can be 
tracked over longer period of time in vivo [21, 22]. 
Various HSC subtypes have been defined using several criteria to distinguish the mature 
blood cell outputs. Mueller-Sieburg et al. have defined different myeloid-biased, lymphoid-
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biased and balanced subtypes based on the dominant lineage in the total number of donor-
derived blood cells (excluding the recipient’s contribution) [4].  
Dykstra et al. studied different differentiation behavior of HSC by their relative contribution 
to the total number of circulating myeloid and lymphoid cells (including both donor and 
recipient HSC). In the latter method HSC subtypes are defined as lymphoid-deficient (α), 
balanced (β) and myeloid-deficient (γ and δ). Both α and β-HSC contribute equally to the 
circulating pool of myeloid cells [3]. Serial transplantation experiments have shown that only 
α and β-HSC remain active during serial transplantation and their unique differentiation 
behavior is maintained in primary transplants over years [2, 3]. In addition, their initial 
expression pattern of differentiation is expressed by their clonally generated daughter cells 
when they are transplanted into secondary recipient mice [2-4, 11].  
Yamamoto et al. defined an intermediate-term-HSC (IT-HS) in addition to previously defined 
short and long-term-HSC (ST- and LT-HSC)  [10, 23, 24]. They proposed using ST-, IT-, and LT-
HSC to classify HSC based on their reconstitution time period [10]. Since granulocytes are 
extremely short-lived, their reconstitution directly reflects HSC activity. Therefore the 
reconstitution of granulocytes (and not other lineages such as erythrocytes, B-cells and T-
cells) was considered as a parameter of this classification [3, 25, 26].  
 
1.1.2 Purification of hematopoietic stem and progenitor cells 
Numerous studies have been conducted to purify HSC and HPC populations using flow 
cytometry. This technique is primarily based on fluorochrome-conjugated antibodies against 
cell surface markers of HSC and HPC and the physiological properties of these cells such as 
high-efflux activity of certain fluorescent dyes. The surface marker combinations to purify 
HSC and HPC are primarily based on Lineage markers, Sca-1, and c-Kit resulting in the so-
called “LSK” (Lineage- Sca-1+ c-Kit+) population [27]. LSK cells comprise a heterogeneous 
population including self-renewing long term HSC and various HPC. Although compared to 
whole BM, LSK cells are about 1000 fold enriched for HSC activity, the majority of these cells 
are multipotent progenitors and only about 1 out of 30 LSK cells is a long-term multilineage 
repopulating cell [28].  
Markers in LSK scheme can be used to further subfractionate this population to distinguish 
HSC from differentiating progenitors. Additional markers included in the LSK scheme, such as 
Tie2 [29], CD34[23], and EPCR[30], can be used to further purify this population. The 
“signaling lymphocyte activation molecule” (SLAM) family of proteins, including CD150, 
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CD48, and CD244 can also be used to enhance the LSK enrichment scheme. CD48 and CD244 
are used to identify and eliminate differentiating progenitor lineage cells, while CD150 
identifies cells with potent stem cell activity [31]. 
The other strategy is to identify HSC based on their high efflux ability of fluorescent dyes 
such as a DNA-binding dye, Hoechst 33342 or a mitochondrial-binding dye, Rhodamine123 
(Table 1)[32-34].  
 
Table 1: Summary of single cell BM reconstitution data  
 Phenotype of cell 
 
Frequency of reconstitution (%) Reference 
LSK CD150
+
 CD48
-
 47 [31] 
CD41
-
 CD150
+
 CD48
-
 45 [31] 
LSK SP
lo
 Thy1.1
lo
 CD34
-
 CD135
-
 35 [35] 
Lin
- 
SP Rho
lo
 33 [36] 
LSK CD34
lo/-
 22 [23] 
CD150
+
CD48
-
 21 [31] 
LSK Thy1.1
lo
 18 [37] 
LSK: Lin-Sca1+c-Kit+; SP: side population (can efflux Hoechst 33342); Rho: Rhodamine [38]. 
 
 
The heterogeneity of LSK cells has been shown by further purifying them with CD34 CD48 
CD150 CD135 cell surface markers. Based on the expression of CD150 and CD48 cell surface 
markers, LSK cells can be divided to three populations. CD150+ CD48- cells can be further 
subdivided based on CD34 expression. CD150+ CD48+ subset is almost entirely CD34+ CD135- 
and CD150+CD48- can be subdivided to CD135+ and CD135- subpopulations.  
The frequency of MPP1, MPP2, MPP3, and MPP4 are 3, 5, 18, and 13 times more than HSC 
frequency in whole murine BM respectively [39] (Figure 2).  
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Figure 2: LSK cell population contains 5 subpopulations. HSC, MPP1, MPP2, MPP3, and MPP4 populations are 
depicted according to their cell surface markers. HSC: hematopoietic stem cells, MPP: multipotent progenitor 
cells, BM: bone marrow. 
 
1.1.3 Regulation of hematopoietic stem cell fate  
 
The task of HSC is to maintain a certain number of cells in each hematopoietic lineage and to 
adapt blood cell production to the need of the organism. This is done through the regulation 
of various processes such as differentiation versus self-renewal, proliferation versus 
quiescence and survival versus apoptosis [40]. The cellular environment (niche) in bone 
marrow contains various cells such as endothelium, adipocytes and osteoblasts which play a 
crucial role in the regulation of HSC [41] (Figure 3). 
Both intrinsic and extrinsic signals such as cytokines, cell-cell contacts or contacts with the 
extracellular matrix in the subendosteal, influence the fate of stem cells. Two hypotheses 
attempt to describe action and interactions of exogenous signals and intrinsic factors [42, 
43].  
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Figure 3: Fate decisions of hematopoietic stem cells. HSC have the unique ability to reconstitute 
hematopoiesis throughout life while keeping the number of stem cells constant (self-renewal). During the 
differentiation process, HSC and progenitor cells must constantly go through fate decisions. Adult 
hematopoiesis is largely dependent on the microenvironment in BM, which consists of a heterogeneous 
mixture of cells, such as stroma, osteoblasts, endothelial cells and extracellular matrix (ECM) [44]. 
The intrinsic, stochastic model hypothesizes that specific factors, such as transcription 
factors, which are important for the appropriate cell fate decisions are expressed in HSC and 
can be up or downregulated by random-based autoregulatory mechanisms. Transcription 
factors can drive the expression of relevant lineage-specific genes, thereby initiating the 
phenotypic change in the progenitor cell down a specific differentiation pathway [45-47]. As 
an example, transcription factor Pax5 controls the development of B-cells by repressing 
lineage-inappropriate genes and activating B-cell-specific genes [48].  According to this 
model, HSC compared to more differentiated progenitor cells express a wide range of genes 
at basal levels [49].  
In another model, exogenous signals can determine the HSC fate via their cognate receptors 
whose cytoplasmic domains activate various pathways involved in survival, proliferation, and 
differentiation [50, 51]. For instance, it is well known that low level of TGF-β1 maintains the 
multiple differentiation potentials of hematopoietic stem and progenitor cells, which is 
associated with its negative controlling effect on cells cycling. TGF-β1 functions as a key 
physiological factor ensuring the maintenance of a stem cell reserve [52]. 
The innovative use of imaging techniques demonstrated the influence of lineage-specific 
differentiation of hematopoietic progenitor cells on single-cell level after the using cytokines 
[40].  
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1.1.4 Process of leukemogenesis  
Accumulation of genetic alterations in HSC causes dysregulation of these cells which finally 
leads to neoplasia. In accordance with available models for the origin and development of 
neoplasia, transformation to leukemia has long been thought to be a multistep process. 
Foulds first proposed a multistep progression model in which a normal cell should go 
through a number of different intermediate stages before a malignancy develops [53-55]. 
This model is consistent with a dysregulation process in myelodysplastic syndrome (MDS) in 
which BM hyperplasia and ineffective hematopoiesis leads to dysplasia. Subsequent events 
involving several genetic mutations such as p53, Rb or ras can enable the subclone to escape 
from apoptotic process and develop to leukemia (Figure 4). 
These genetic aberrations can be initiated by exogenous factors such as chemicals, radiation 
and chemotherapeutic agents or by endogenous random circumstances. Extensive damages 
to the genetic material are normally recognized by the cell and these cells are eliminated by 
apoptosis [55].  
 
 
Figure 4. Hypothetical model for the progression of acute myeloid leukemia (AML) involving 5q loss. Model 
of abnormal myeloproliferative evolution in which early events, including alterations in cytokine response and 
loss of heterozygosity (5q), are followed by activation of at least one protooncogene coupled with the 
successive loss of a tumor suppressor gene. Adapted from[55]. MDS: myelodysplastic syndrome [55] . 
 
Due to the accessibility of tumor material and successful cytogenetic techniques which 
detect chromosomal alterations, acute leukemia is one of the best characterized genetic 
diseases. Childhood acute lymphoblastic leukemia (ALL) is characterized by recurring 
aneuploidies (e.g., high hyperdiploidy and hypodiploidy) and chromosomal translocations 
such as t(9;22) BCR-ABL1 and rearrangement of the TLX1,TLX3, LYL1 and MLL genes in T-
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lineage ALL (T-ALL) [56-58]. With the exception of BCR-ABL1 these abnormalities are less 
common in adult ALL [59].  
Development of high throughput technology has enabled to investigate the mutation status 
at both RNA and DNA level and detect mutations in leukemic cells with no cytogenetic 
abnormalities. It is shown that leukemic clones carry several genetic changes which 
contribute to the development of leukemia [60-62]. Genetic analyses of leukemic clones 
have demonstrated the occurrence of several mutations per leukemic cell and thus different 
subclones with specific changes. This allows tracking both the dynamics and development of 
individual subclones and suggests that several clones are able to give rise to leukemia [63, 
64].  
 
1.2 Wiskott-Aldrich Syndrome 
Wiskott–Aldrich Syndrome (WAS) is an X-linked primary immunodeficiency disorder that is 
characterized by severe immunodeficiency, microthrombocytopenia, eczema and an 
increased incidence of autoimmunity and malignancies [65]. The incidence of this rare 
disorder is approximately one to four cases per 1,000,000 live male births [66] [67].  
The gene responsible for WAS is located on the short arm of the X chromosome at Xp11.22–
p11.23 [65]. The WAS gene encodes the WAS protein (WASp), which is a 502-amino acid 
protein. WASp is involved in actin polymerization and associated coupling of receptor 
engagement, signaling events, and cytoskeletal rearrangement and is exclusively expressed 
in hematopoietic cells [68, 69]. There is a strong correlation between the level of WASp and 
the severity of WAS. Complete WASp absence leads to a pronounced defect in the function 
of multiple hematopoietic cell lineages, resulting in thrombocytopenia with small platelets 
and progressive lymphopenia with abnormal lymphoid and myeloid cell function [70]. On the 
other hand, decreases in WASp levels have variable effects on the function of the different 
cell types, especially platelets [71]. 
WAS disease is caused by mutations in the WAS gene expressed exclusively in hematopoietic 
cells. Since actin cytoskeleton plays a prominent role in the basic mechanisms of cell 
adhesion and migration, the effects of WAS gene mutations on these processes has become 
more substantial [72-74]. Heterogeneous mutations spanning the entire WAS gene have 
been described. These mutations in WAS alter the function or expression of the WASp 
intracellular protein. Around 300 unique mutations spanning the WAS gene have been 
described. The most frequent ones are missense mutations, followed by splice-site 
mutations, deletions, nonsense mutations, insertions, and complex mutations [65, 70, 75]. 
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Most missense mutations are located in exons one to four, splice-site mutations are 
predominantly in introns six to ten, whereas nonsense mutations, insertions, deletions, and 
complex mutations are distributed throughout the whole WAS gene [76, 77]. The effect of a 
given mutation on WASp expression correlates with severity of disease with some 
exceptions. In general, mutations that abolish WASp expression or result in the expression of 
a truncated protein are associated with WAS disease [76, 78, 79]. 
 
1.2.1 Treatments of Wiskott–Aldrich Syndrome 
1.2.1.1 Hematopoietic stem cell transplantation 
Despite advances in diagnosis and clinical care, the prognosis of WAS disease remains poor. 
Allogeneic hematopoietic stem cell transplantation (HSCT) can be considered, especially if a 
human leukocyte antigen (HLA)–identical related sibling donor is available [80]. The best 
transplantation outcome has been achieved with HLA-identical sibling donors and matched 
unrelated donors when the age of the recipient is less than five years at the time of the 
transplant [81, 82]. Acute or chronic graft-versus-host disease (GVHD) is observed especially 
in the first year after HSCT but can persist longer, and is treated with immunosuppression. 
Recently, autoimmunity independent of GVHD has been observed in patients with WAS 
following HSCT, and is associated with reduced donor chimerism [83, 84].  
1.2.1.2 Gene therapy 
Gene therapy is an alternative to HSCT in the treatment of WAS [85-87]. To avoid the 
immunological barriers imposed by GVDH in allogeneic HSCT, autologous gene-modified 
HSCT has been used [88]. In addition, recent advances in gene therapy make it an attractive 
alternative to HSCT for WAS, especially in cases where no HLA-matched donor is available.  
The procedure of gene therapy consists of isolating autologous HSC (CD34+) from the 
patient, transducing the cells ex vivo with an RV that expresses WASp as a transgene, and 
then reinfusing them back into the patient (Figure 5) [89]. After hematopoietic 
reconstitution, the clonality, kinetics and contribution of gene - corrected cells to blood 
formation can be observed by means of specific PCR technologies [90-93]. The stable 
persistence of the corrected gene results in clinical improvement. 
  
Introduction 
10 
 
 
Figure 5. Retroviral gene transfer into hematopoietic stem cells in gene therapy. The corrected transgene is 
introduced to CD34+ cells by gamma retroviral vectors. After transduction of the hematopoietic progenitor 
cells, they are transferred back into the patient. The gene-corrected cells can be analyzed using LAM-PCR. 
Adapted from [94] . IS: integration site.  
 
After WAS gene therapy trials with gammaretroviral vector, 9 out of 10 treated patients 
showed sustained engraftment and correction of WASp expression in lymphoid and myeloid 
cells and platelets. Gene therapy resulted in partial or complete resolution of 
immunodeficiency, autoimmunity, and bleeding diathesis [95, 96].  
One of the side effects of gene therapy is the integration of gammaretroviral vectors into the 
host genome which might cause serious consequences (section 1.3.1). It was observed that 7 
out of 10 WAS patients treated with gene therapy developed leukemia two to five years 
after bone marrow transplantation (BMT) [97].  
 
Efforts at improving the efficacy and safety of autologous gene-modified HSCT have recently 
focused on using of lentiviral vectors. Three patients with WAS received autologous gene-
modified HSCT using cells transduced with lentiviral vectors encoding for WASp [85, 86]. 
Stable and durable integration of the corrected gene and expression of WASp was noted 
[98]. No insertional oncogenesis-associated events have been reported so far; however, 
long-term safety and efficacy in gene therapy trial using lentiviral vectors are still being 
studied. 
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1.3 Retroviral vector system 
Viral vectors contain viral elements on the transfer vector. These elements include viral 
packaging signal (ψ), which is involved in regulating packaging the retroviral RNA genome 
into the viral envelope during replication, a promoter which initiates the transcription of the 
transgene and a polyadenylation signal which marks the end of ectopic RNA. Primer binding 
site (PBS) is required for initiating reverse transcription. Polypurine tract (PPT) allows the 
viruses to generate double strand DNA from RNA genome. Long terminal tandem repeats 
(LTRs) are identical sequences at 5´ and 3´ ends of viral genome which are necessary for the 
process of DNA synthesis. Moreover, they are used by viruses to insert their genetic material 
into the host genomes. To reduce the risk of productive recombination and replication by 
the viral vectors and increase their safety level, several accessory viral genes such as vif, vpr, 
vpu and nef were removed [99].  
Virus particles encoding transgenes can be produced in a packaging cell line such as HEK293. 
Packaging cells have been either engineered to stably express viral proteins such as capsid 
and reverse transcriptase or they get transfected by the helper plasmids encoding viral 
genes. Produced viral particles can transduce target cells and integrate their genetic material 
into the host genome after reverse transcription (Figure 6).  
Viral vectors are widely used in gene therapy trials to stably integrate the coding sequences 
of the therapeutic genes into patient’s genome [94, 99-103].  
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Figure 6: Packaging and transduction process of retroviral vectors. Retroviral vectors are generated by co-
transfection of a packaging cell line like HEK293 cells with the cDNA expressing transfer plasmid along with two 
helper/packaging plasmids which encode the structural capsid (gag) and envelope (env) proteins, reverse 
transcriptase and integrase enzymes. Packaging cells produce viral particles, whose genome only encodes 
sequences from the transfer plasmid, and can transduce the target cells. Transduction starts when the viral Env 
protein interacts with the cellular receptor and enters the target cell. The RNA genome is reverse transcribed 
into dsDNA which then enters the nucleus, is integrated into the host genome and gets expressed by the host 
cell’s machinery. Proviral mRNA contains a packing signal for the viral envelope (ψ), a binding site for primer 
(PBS) during reverse transcription, and a polypurine tract (PPT) which allows the synthesis of double-stranded 
DNA. Adapted from [104]. 
 
1.3.1 Insertional mutagenesis: the side effect of retroviral gene transfer  
Insertional vectors are gene delivery tools in clinical gene therapy, providing constant 
transgene expression in the host cell genome [86, 105, 106]. However, severe side effects of 
gammaretroviral vector insertion have raised concern about the safety of gene therapy 
(section 1.2.1.2) [107-109]. Two to five years after gammaretroviral gene therapy trial, seven 
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patients developed acute leukemia (one acute myeloid leukemia (AML), four T cell acute 
lymphoblastic leukemia (T-ALL), and two primary T-ALL with secondary AML after 
chemotherapy) [97].  
Insertional analysis demonstrated that vector integration occurred preferentially in the 
vicinity of transcription start sites and was clustered in regions proximal to proto-oncogenes. 
It has been shown that the integration of gammaretroviral vector used in gene therapy is 
semi-random with the preference of integrating in ±5-10 kb from the transcription start sites 
(TSS) [94, 99-103]. Due to the strong enhancer and promoter in the LTR region of RV, other 
genes in vicinity of RV integration might get transcriptionally activated because of insertional 
mutagenesis (Figure 7). This constant activation might lead to clonal expansion up to 
malignant transformation over time. Studying the IS in gene therapy patients treated for 
primary immune deficiency diseases revealed that years after BMT, clones carrying the IS in 
vicinity of specific genes such as LMO2 and MDS1/EVI1 become dominant over other clones. 
Analyzing the IS repertoire of WAS gene therapy patients which developed leukemia reveals 
that LMO2 is one of the most frequently targeted locus which gets activated due to 
insertional mutagenesis [97]. The gene therapy-induced leukemia and the mouse models 
suggest that enforced expression of LMO2 causes a clonal growth advantage in T-cell lineage 
which eventually leads to T-cell acute lymphoblastic leukemia (T-ALL) [110, 111].  
 
 
Figure 7: Insertional mutagenesis following retroviral integration. Genes in vicinity of retroviral integration 
might get activated by proviral enhancer/promoter. LTR: long tandem repeat.  
 
The genotoxicity risk of gammaretroviral vectors can be reduced by replacing the strong 
promoter-enhancer of vector LTR with a relatively weak internal promoter derived from 
endogenous genes to produce a self-inactivating (SIN) vector [112]. It was shown that SIN 
lentiviral vectors with a promoter derived from the human phosphoglycerate kinase gene 
(PGK) did not accelerate tumor induction in lymphoma-prone mice, in contrast to 
gammaretroviral vectors with strong enhancer–promoter sequences located in the LTRs 
[113]. 
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1.3.2  Monitoring clonal dynamics of marked hematopoietic stem cells by LAM-PCR 
Several PCR-based methods are available for the identification and characterization of 
unknown flanking DNA sequences [91, 92, 103, 114].  
The linear amplification-mediated PCR (LAM-PCR) proved to exhibit the highest sensitivity, 
allowing the detection of various vector integration sites (IS) in one sample. LAM-PCR 
developed by our group characterizes unknown DNA regions flanking viral IS with a 
sensitivity down to single-cell level [101].The integration of retroviral vectors into distinct 
chromosomal sites creates unique sequences between the genomic DNA and 5’ and 3’ LTRs 
of the vector that makes vector IS a clonal marker of each transduced cell and all of its 
progeny [101].  
The broad application spectrum of LAM-PCR has been approved by its application as a tool 
for the molecular follow up of gene-modified cells [109, 115-117]. The combination of this 
sensitive PCR method with high-throughput sequencing allows detecting the IS repertoire, 
clonality and the viral integration patterns in pre-clinical and clinical studies [87, 116, 118-
120].  
  
Figure 8: LAM-PCR detects the precise position of viral IS in the genome. A PCR product which starts from the 
known sequence of the vector (LTR) extends through the unknown neighboring genome. After performing 
LAM-PCR and sequencing the PCR-amplified DNA fragments the precise integration position within the genome 
will be revealed. LAM-PCR: linear amplification-mediated PCR; LTR: long tandem repeat.  
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LAM-PCR is a multiple step procedure. LTR-specific, biotinylated primers are used to amplify 
the genome-RV junctions. Single-stranded DNA fragments composed of the known primer-
vector-sequence and unknown adjacent part of the host cells genome were immobilized on 
streptavidin-coated magnetic beads. Double-stranded DNA was synthesized and 
subsequently digested with restriction enzymes. A restriction-site-specific linker of a known 
sequence was coupled to the remaining double-stranded DNA. The DNA fragments were 
denatured and removed from the solid phase. Single-stranded DNA was further amplified 
using linker-specific and nested primers. Finally, amplified DNA was purified, concentrated 
and submitted for high resolution gel electrophoresis (Figure 8). To detect the precise 
location of the vector IS in the genome, amplified DNA was sequenced by high-through-put 
next generation sequencing platforms [101, 121]. 
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Specific aims 
In clinical gene therapy studies, retroviral vectors (RV) are used to stably integrate a 
therapeutic transgene into the host cell genome promoting its long term expression in all 
progenies of transduced blood cells. To monitor clonal selection and vector-associated 
genotoxicity in individual subjects the complete integration site (IS) repertoire has been 
analyzed in Wiskott Aldrich Syndrome (WAS) gene therapy patients using highly sensitive 
Linear Amplification Mediated (LAM) PCR. Detailed IS analyses proved that RV integrations 
are semi-randomly distributed and that common integration sites (CIS) cluster close to 
transcription start sites of genes possibly pointing to an in vivo selection. Moreover, we have 
observed that therapeutic-vector-mediated transcriptional activation of neighboring genes 
can lead to leukemia. Analyzing the IS repertoire in normal individuals enabled us to monitor 
the dynamics of each individual RV-marked clone in highly polyclonal human post-transplant 
hematopoiesis. We hypothesize that systematic re-analysis of this large and unique clinical IS 
dataset can help to identify candidate genes involved in the regulation of hematopoietic 
stem cells. Towards a precise selection and a further molecular understanding of the 
regulatory role of candidate genes in hematopoiesis determined by gammaretroviral CIS we 
specifically aim: 
Aim 1: To select candidate hematopoietic regulatory genes  
We aim to establish a strategy for selecting novel hematopoietic regulatory genes based on 
systematically investigating the genome-wide RV integration site pattern obtained from 10 
clinical WAS gene therapy patients. Moreover, we aim to assess the contribution of human 
hematopoietic cell clones harboring IS close to the candidate genes to blood formation in 
individual patients for up to four years. To further select for stem cell relevant genes we seek 
to determine the endogenous expression level of each candidate in well-defined murine 
hematopoietic stem and progenitor cell populations.  
Aim 2:  To examine the impact of selected candidate genes on hematopoietic stem cells in 
vitro and in vivo 
To validate and characterize the molecular mechanism of the selected candidate genes in 
hematopoietic cells lentiviral based overexpression vectors will be used. We aim to 
investigate the influence of the selected genes on proliferation, viability and cytokine 
dependency in vitro as well as long term multilineage reconstitution and self-renewal of 
hematopoietic primary cells in vivo.  
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Systematic identification of novel candidate regulatory genes in meta-datasets derived from 
a large number of gene therapy studies and subsequent validation in vitro and in vivo will 
help us to gain new insights into the biology of post-embryonic hematopoiesis. 
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3 Material and methods 
 
3.1 Materials 
3.1.1 Equipment and devices 
Equipment  manufacturer  
Analytical Balance TE 124S Sartorius, Göttingen 
Biofuge® pico Heraeus, Hanau 
Camera Lumix DMC-FZ50  Panasonic, Hamburg 
Centrifuge inserts Kendro, Langenselbold 
Centrifuge Multifuge® 3SR  Heraeus, Hanau 
Cryobox Nalgene Thermo Fisher Scientific, Schwerte 
Electrophoreses Power Supply 200/2000  Elchrom Scientific, Cham 
Flow Cytometer BD™ LSRII Becton, Dickinson and Company, 
Heidelberg 
Flow Cytometer FACS Aria™ Cell Sorter Becton, Dickinson and Company, 
Heidelberg 
Fluorescence Microscope Axiovert 200  Zeiss, Oberkochen 
Freezer -20°C  Liebherr, Biberach an der Riss 
Freezer -80°C  Sanyo (Panasonic), Hamburg 
Fridge 4°C  Liebherr, Biberach an der Riss 
Gel Documentation  Peqlab, Erlangen 
Gel Electrophoreses Chamber  Biometra, Göttingen 
Incubator Heracell® 150  Thermo Fisher Scientific, Schwerte 
Isoflurane Vaporizer Vapor 19.3  Dräger, Lübeck 
LightCycler® 480 Real-Time PCR Roche, Mannheim 
 Material and methods 
19 
 
Light Microscope Zeiss, Oberkochen 
Microplate Reader  Tecan, Männedorf 
Microwave  Bartscher, Salzkotten 
Mini Protean®  Tetra Cell BioRad, Munich 
Molecular Imager®  ChemiDoc™ XRS+ BioRad, Munich 
Multipette Plus Eppendorf, Hamburg 
NanoDrop® Spectrophotometer ND-1000  Peqlab, Erlangen 
Neubauer counting chamber Marienfeld, Lauda-Königshofen 
Nitrogen System German-Cryo, Jüchen 
PCR-Thermocycler Landgraf, Langenhagen 
Pipetboy acu  Integra Biosciences, Fernwald 
Pipettes Research® (10μl; 20μl; 200μl; 1000μl)  Eppendorf, Hamburg 
Power Pac™ HC Power Supply BioRad, Munich 
Precision Balance TE3102S  Sartorius, Göttingen 
Rotator Reax2 Heidolph, Schwabach 
Safety Cabinet Herasafe® KS Thermo Fisher 
Scientific 
Thermo Fisher Scientific, Schwerte 
Shaking incubator Axon, Kaiserslautern 
Submerged Gel Electrophoresis Apparatus SEA 
2000® 
Elchrom Scientific, Cham 
TC10™ Automated Cell Counter BioRad, Munich 
Thermo Cycler TPersonal  Biometra, Göttingen 
Thermo Mixer comfort  Eppendorf, Hamburg 
Trans-Blot®  semi-dry cell BioRad, Munich 
Transilluminator Biotec-Fischer, Reiskirchen 
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Ultracentrifuge L8-M with Rotor SW27  Beckman Coulter, Krefeld 
Vacuum pump  Merck Millipore, Darmstadt 
Video documentation system Peqlab, Erlangen 
Vortexer MS1 IKA, Staufen 
Water Bath Haake SWB25  Thermo Fisher Scientific, Schwerte 
Water treatment plant TKA, Niederelbert 
 
3.1.2 Plastic and disposables  
Cell Culture Flasks, EasyFlasks™ (25cm2; 
75cm2; 175cm2)  
Nunc (Thermo Fisher Scientific), 
Schwerte 
Cell Culture Plates (6-; 12-; 24-; 48-; 96-
well) 
Becton, Dickinson and Company, 
Heidelberg 
nylon cell strainer (40-100 µm pore size) 
Becton, Dickinson and Company, 
Heidelberg 
cotton swabs, sterile 
Noba Verbandmittel Danz GmbH, 
Wetter 
Cover Glasses  Marienfeld, Lauda-Königshofen 
Cryotubes  Corning, Kaiserslautern 
FACS Tubes, BD™ Falcon™ Round-Bottom 
Tube (5ml)  
Becton, Dickinson and Company, 
Heidelberg 
Filter (0.22µm pore size) Merck Millipore, Darmstadt 
Hollow Needle  
Becton, Dickinson and Company, 
Heidelberg 
Hollow Needle, blunt end 18G 
Becton, Dickinson and Company, 
Heidelberg 
Lab Gloves (Nitril)  Microflex, Reno 
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Parafilm Pechiney Plastic Packaging, Chicago 
PCR reaction tube (V=0,2 ml) Genaxxon, Ulm 
Petri dish (d=10 cm, 3.5cm) Genaxxon, Ulm 
Petri dish Nunclon™ (d=15 cm) Thermo Electron, Langenselbold 
Pipette Tips (200μl, extended)  Thermo Fisher Scientific, Schwerte 
Pipettes (V=2 - 50 ml) Genaxxon, Ulm 
Pipette tips (V=10/20/200/1000 µl) Starlab, Hamburg 
PVDF membrane  BioRad, Munich 
scalpel  Feather Safety, Osaka 
Stericup vacuum filtration system Merck Millipore, Darmstadt 
Syringe (2,5/5/20/50 ml) Omnifix® Solo B. Braun, Melsungen 
Twin.tec PCR plate 96 well Eppendorf,  Hamburg 
Ultra Low Attachment Flasks  Corning, Kaiserslautern 
Ultracentrifuge tubes Beranek Laborgeräte, Weinheim 
Whatman filter paper Protean® BioRad, Munich 
3.1.3 Bacteria culture 
1x LB Medium 
reagents  manufacturer  amount 
Luria Broth Base (LB) Invitrogen, Darmstadt 25g 
H20  Ad 1000ml 
Autoclaved and stored at 4°C, antibiotic was added before use. 
 
reagents manufacturer  
SOC-Medium (OneShot-Kit) Invitrogen, Darmstadt 
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LB-Agar 
reagent manufacturer amount  
Luria Broth Base (LB)  Invitrogen, Darmstadt 25g 
Agar Sigma-Aldrich, Munich 12,5g 
H20  Ad 1000ml 
The solution was autoclaved, cooled down at 60 ° C in a water bath. Antibiotic was added 
before pouring to plates.  After solidification the plates were kept at 4 ° C. 
 
3.1.4 Cell culture 
HEK-293T and HeLa cells 
reagent manufacturer amount 
Iscove’s modified Dulbecco’s Medium 
(IMDM) 
Gibco® Invitrogen, 
Darmstadt 
500ml 
+ L-Glutamine (200mM) Gibco® Invitrogen, 
Darmstadt 
5ml 
+ FBS, heat-inactivated, filter sterilized  Biosera, Sussex 50ml 
32D cells 
reagent manufacturer amount 
Roswell Park Memorial Institute (RPMI) Gibco® Invitrogen, 
Darmstadt 
100ml 
+ L-Glutamine (200mM) Gibco® Invitrogen, 
Darmstadt 
1ml 
+ FBS, heat-inactivated, filter sterilized  Biosera, Sussex 10ml 
+WEHI-3B supernatant produced according 
to (3.2.2.3.3) 
10ml 
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WEHI-3B cells 
reagent manufacturer amount 
Dulbecco’s Modified Eagle Medium (DMEM)  Gibco® Invitrogen, 
Darmstadt 
500ml 
+ L-Glutamine (200mM) Gibco® Invitrogen, 
Darmstadt 
5ml 
+ FBS, heat-inactivated, filter sterilized  Biosera, Sussex 50ml 
 
FDCP-Mix cells 
reagent manufacturer amount 
IMDM Gibco® Invitrogen, 
Darmstadt 
500ml 
+ L-Glutamine (200mM) Gibco® Invitrogen, 
Darmstadt 
5ml 
+ FBS, heat-inactivated, filter sterilized  Biosera, Sussex 100ml 
+ rmIL3 R&D Systems, 
Wiesbaden 
10 ng/ml 
3.1.5 Freezing and thawing medium 
Freezing medium 
reagent amount 
respective cell medium 55% 
FBS 30% 
DMSO 15% 
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Thawing medium 
reagent amount 
respective cell medium 80% 
FBS 20% 
  
3.1.6 Cytokines, medium supplements and solutions for cell culture 
Cytokines 
reagents  manufacturer  
rmFlt3L R&D Systems, Wiesbaden 
rmIL3 R&D Systems, Wiesbaden 
rmSCF R&D Systems, Wiesbaden 
rhTPO R&D Systems, Wiesbaden 
Medium supplements and solutions for cell culture 
reagents  manufacturer 
Dulbecco’s Modified Eagle Medium Pulver  Gibco® Invitrogen, Darmstadt 
Dulbecco’s phosphate buffered saline (DPBS) Gibco® Invitrogen, Darmstadt 
Fetal Bovine Serum (FBS) PAN Biotech, Aidenbach; Biosera 
Hank’s balanced salt solution (H) Sigma-Aldrich, Munich 
MethoCult M3434 StemCell Technologies, Grenoble 
MethoCult M3630 StemCell Technologies, Grenoble 
MethoCult H4230 StemCell Technologies, Grenoble 
Polybrene Millipore, Schwalbach 
Polyethylenimin (PEI) Sigma-Aldrich, Munich 
Protaminsulfate Sigma-Aldrich, Munich 
Trypsin-EDTA 0,05% Invitrogen, Darmstadt 
 Material and methods 
25 
 
 
Antibiotics 
reagents manufacturer  
Ampicillin (100mg/ml mit H2O) Sigma-Aldrich, Munich 
 
3.1.7 Antibodies  
Antibodies for Western blot 
reagent manufacturer  
mouse-anti-Human-α-Tubulin Invitrogen, Darmstadt 
EVL (C-17), sc-66527 Santa Cruz, Heidelberg 
PLCB4 (A-9), sc-166131 Santa Cruz, Heidelberg 
 
Antibodies for flow cytometry 
reagent manufacturer  
CD16/CD32 BD Biosciences, Heidelberg 
anti mouse CD45.1-PE BD Biosciences, Heidelberg 
anti mouse CD45.2-PerCPCy5.5 BD Biosciences, Heidelberg 
anti mouse CD3-PerCPCy5.5 BD Biosciences, Heidelberg 
anti mouse Ter119-PECy7 BD Biosciences, Heidelberg 
anti mouse CD11b-PerCPCy5.5 BD Biosciences, Heidelberg 
anti mouse Ly6G-Alexa700 BD Biosciences, Heidelberg 
anti mouse CD117-PE BD Biosciences, Heidelberg 
anti mouse Sca-1-Alexa Fluor700 eBiosciences, Frankfurt 
anti mouse Lineage cocktail-APC BD Biosciences, Heidelberg  
anti mouse CD150-PE/Cy7 Biolegend, Fell 
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anti mouse CD135-PE BD Biosciences, Heidelberg 
anti mouse CD48-PerCpCy5.5 BD Biosciences, Heidelberg 
anti mouse CD34-FITC BD Biosciences, Heidelberg 
mouse IgG2a,FITC BD Biosciences, Heidelberg 
mouse IgG2a,κ-PE-Cy7 BD Biosciences, Heidelberg 
mouse IgG2a,κ- Alexa Fluor700 BD Biosciences, Heidelberg 
mouse IgG1,κ-PE BD Biosciences, Heidelberg 
mouse IgG2a,κ-PE BD Biosciences, Heidelberg 
mouse IgG2a,κ- PerCPCy5.5 BD Biosciences, Heidelberg 
mouse IgG1,κ-APC  BD Biosciences, Heidelberg 
 
3.1.8 PCR primers and reagents 
RT-PCR primers 
designation sequence(5‘-3‘) 
PLCB4_Fwd ATGCGGGTACCTTCTCAAGC 
PLCB4_Rev TTTCCGTATGGTGTCGGTGG 
ZNF217_Fwd TGAGGATGGACTCCCTGACG 
ZNF217_Rev GCTGCGGCATACTCACAGAA 
IRF2BPL_Fwd AGATGCTAGCTGTCCCATGC 
IRF2BPL_Rev TGTTCCTCACCGAGCTTCAG 
EVL1_Fwd  ATGAGTGAACAGAGTATCTGCC 
EVL1_Rev  TCTTTGCCACAGACGGGGTT 
ZNF217_opt Fwd ACCCCGAAGTGCTGATGATG 
ZNF217_opt Rev ACTTGCTGTGAGGGCTGAAA 
EVL1_opt Fwd ATCTACCACAACACCGCCAG 
 Material and methods 
27 
 
EvL1_opt Rev AGGTGGTGGCTTCCTCTTTG 
IRF2BPL_opt Fwd AAACAGAGCCGAGGAATGGG 
IRf2BPL_opt Rev GCCGGTGGGATACTCGATG 
PLCB4_opt Fwd GAAGTCCGAGGGCAAAGAGG 
PLCB4_opt Rev CACCATGTAGGTGAAGCCGA 
LRRC33_opt Fwd CCGACAACAGACTGAGCGAG 
LRRC33_opt Rev TCGAAGATGCTGTCGTCCAG 
TBP-Mus_Fwd-new CCT TCA CCA ATG ACT CCT ATG AC 
TBP-Mus_Rev-new CAA GTT TAC AGC CAA GAT TCA C 
 
Genotype-PCR primers 
 
Genotype-PCR reagents 
 
 
 
 
  
designation sequence(5‘-3‘) 
PLCb4-MT_Rev GCT ACT TCC ATT TGT CAC GTC C 
PLCb4-WT-MT_Fwd TGT CGG TGT TGG GTG AGA C 
PLCb4-WT_Rev GGA TGT TCG TGG TAG CAC CT 
reagents manufacturer  
dNTPs (mM) Genaxxon, Ulm 
Red Taq Master Mix Genaxxon, Ulm 
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3.1.9 Plasmids 
designation function 
 
p101 pMDL gag pol rre CMV-driven HIV-1 construct expressing 
Gag and Pol with RRE (Rev responsive 
element)  
p102  pRSV-rev   RSV-driven HIV-1 construct expressing 
Rev  
p103  pMD2.VSVG CMV-driven construct expressing VSV-
G  
pCCLsin.ppt.PGK.EVL.IRES.eGFP.Wpre PGK-driven construct expressing EVL 
and GFP 
pCCLsin.ppt.PGK.ZNF217.IRES.eGFP.Wpre PGK-driven construct expressing 
ZNF217 and GFP 
pCCLsin.ppt.PGK.IRF2BPL.IRES.eGFP.Wpre PGK-driven construct expressing 
IRF2BPL and GFP 
pCCLsin.ppt.PGK.PLCB4.IRES.eGFP.Wpre PGK-driven construct expressing PLCB4 
and GFP 
pCCLsin.ppt.PGK.LRRC33.IRES.eGFP.Wpre PGK-driven construct expressing 
LRRC33 and GFP 
pCCLsin.ppt.PGK.IRES.eGFP.Wpre PGK-driven construct expressing GFP 
 
3.1.10 Chemicals and reagents  
reagents manufacturer  
Agarose   Serva, Heidelberg 
Aqua ad injectabilia (aqua dest)  B. Braun, Melsungen 
Baytril®  Bayer, Leverkusen 
Bovine Serum Albumin Sigma-Aldrich, Munich 
Dimethylsulfoxide (DMSO)  Sigma-Aldrich, Munich 
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DNA ladder 100 bp  Invitrogen, Darmstadt 
DNA ladder 1kb Invitrogen, Darmstadt 
Ethanol  Sigma-Aldrich, Munich 
Ethidiumbromide (0.07%) AppliChem AppliChem, Darmstadt 
Fluorogold Invitrogen, Darmstadt 
Isopropyl alcohol  Sigma-Aldrich, Munich 
Loading Buffer (5x)  Elchrom Scientific, Cham 
MgCl2  100mM Sigma-Aldrich, Munich 
Propidiumiodid  Invitrogen, Darmstadt 
RNase/DNase free water Ambion, Darmstadt 
Sodium azide pure (NaN3) AppliChem, Darmstadt 
Sodium Chloride (NaCl) VWR International, Vienna 
Tris HCl pH 7.5 (1M) USBiological, Swampscott 
Precision Plus Protein™ Standard Bio Rad, Munich 
 
3.1.11 Enzymes and reaction buffers for cloning 
T4 DNA-Ligase + buffer New England Biolabs, Frankfurt 
Restriction endonuclease digestion buffers New England Biolabs, Frankfurt 
Restriction endonucleases New England Biolabs, Frankfurt 
3.1.12 Commercial kits 
designation manufacturer 
Blood and Tissue Kit Qiagen, Hilden 
EasySep StemCell Technologies, Grenoble 
EndoFree® Plasmid Purification Kit Qiagen, Hilden 
SYBR® Select Master Mix Roche, Mannheim 
Plasmid Miniprep DNA Purification Kit GeneMATRIX 
QIAquick® Gel Extraction Kit  Qiagen, Hilden 
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QIAquick® PCR Purification Kit  Qiagen, Hilden 
RNeasy Micro Kit Qiagen, Hilden 
RNeasy Mini Kit Qiagen, Hilden 
Super-Script III Synthesis-Kit  Invitrogen, Darmstadt 
Topo-TA-Cloning® Kit Invitrogen, Darmstadt 
Western Lightning Plus-ECL Perkin Elmer, Rodgau 
ARCTURUS® PicoPure® RNA Isolation Kit Life Technologies, Frankfurt 
CellTiter-Glo® Luminescent  Promega, Mannheim 
Dual-Light® Luciferase & β-Galactosidase Reporter 
Gene Assay System  
 
Life Technologies, Frankfurt 
3.1.13 Western blot buffers and reagents 
RIPA-Buffer  
reagents final concentration  
NaCl 150mM 
Tris 50mM 
Nonidet P-40 1% 
Na-Deoxycholate 0,5% 
Sodium monododecyl sulfate 1% 
 pH7,5 
 
1:25 Roche Complete Proteaseinhibitor was added to RIPA right before preparing the cell 
lysate.  
 
reagents manufacturer amount 
Complete® Proteaseinhibitor Roche, Mannheim 1 tablet   
H2O  2 ml 
Aliquote and stored at -20°C 
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Lower Gel buffer (LGP) 
reagents final concentration 
TRIS 1,5M 
Natriumdodecylsulfat (20%) 0,4% 
 pH8,8 
 
Upper Gel Buffer (UPG) 
reagents final concentration 
TRIS 0,5M 
Sodium monododecyl sulfate 
(20%) 
0,4% 
 
Resolving gel (1x) 
reagents 5% 7,5% 10% 13% 15% 
LGB (ml) 2 2 2 2 2 
H2O (ml) 4,6 4 3,3 2,5 2 
Acrylamide (30%; ml) 1,3 2 2,6 3,4 4 
APS (10%; µl) 50 50 50 50 50 
TEMED (µl) 5 5 5 5 5 
 
Stacking gel 
reagents 5% 
UGB (ml) 1,25 
H2O (ml) 3 
Acrylamide(30%; ml) 0,8 
APS (10%; µl) 50 
TEMED (µl) 5 
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SDS-running buffer (10x) 
reagents final concentration 
TRIS 25mM 
Glycine 190 mM 
Sodium dodecyl sulfate (20%) 1% 
 
Blotting buffer 
 reagents final concentration  
TRIS 25mM  
Glycine 150mM  
Methanol 10% optional 
Sodium dodecyl sulfate (20%) 1% optional 
 pH8,5  
 
Washing buffer (PBS-T, 10x) 
reagents final concentration 
NaCl 1,37M 
Na2HPO4 100mM 
K2HPO4 20mM 
KCl 27mM 
Tween-20 0,5% 
 
Blocking buffer (TBS-T, 10x) 
reagents final concentration 
NaCl 1,5M 
TRIS-HCl pH7,5 100mM 
Tween-20 0,5% 
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Solution for primary antibody 
reagents final concentration 
BSA 1,25% 
Washing buffer 1x PBS-T 
Sodium azide 10% 1:1000 
 
Solution for secondary antibody 
reagents final concentration 
milk powder 5% 
Washing buffer 1x PBS-T 
 
3.1.14 Bacteria strains 
designation genotype 
One Shot® TOP10 Chemically 
Competent E. coli  
 
F– mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 ΔlacX74 
recA1  
araD139 Δ(ara leu) 7697 galU galK rpsL (StrR) endA1 nupG 
3.1.15 Cell lines 
designation manufacturer  
293T ATCC, Wesel/DSMZ, Braunschweig 
 
HeLa ATCC, Wesel/DSMZ, Braunschweig 
 
FDCP-Mix DSMZ, Braunschweig 
 
 32D  ATCC, Wesel/DSMZ, Braunschweig 
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C1498 ATCC, Wesel/DSMZ, Braunschweig 
 
3.1.16 Mouse strains 
designation manufacturer  
C57Bl/6J Jackson Laboratories, Bar Harbor, ME, USA 
B6.SJL-Ptprca Pepcb/BoyJ Jackson Laboratories, Bar Harbor, ME, USA 
B6.129S1-Plcb4tm1Dwu/J Jackson Laboratories, Bar Harbor, ME, USA 
3.1.17 Surgical instruments  
Cotton Swabs  Böttger, Bodenmais 
Forceps, Moria Ultrafein  Fine Science Tools, Heidelberg 
Forceps, standard anatomical  Fine Science Tools, Heidelberg 
Forceps, standard surgical  Fine Science Tools, Heidelberg 
Insulin Syringe 0.5ml, 27G Becton, Dickinson and Company, Heidelberg 
Scalpels  Feather Safety, Osaka 
Scissors, standard surgical  Fine Science Tools, Heidelberg 
Ear punch Fine Science Tools, Heidelberg 
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3.2 Methods 
3.2.1 Molecular biology methods 
 Transformation of competent E.coli bacteria  3.2.1.1
Bacteria exhibit distinct features which make them ideal organisms to amplify DNA. For this 
work, One Shot® TOP10 chemically competent E. coli was used. The competent state was 
achieved by Ca2+-treatment leading to masking of the negatively charged outer bacterial 
membrane which consists of lipopolysaccharides and phospholipids. The negatively charged 
DNA molecules are attracted and can enter the cell upon heat shock which weakens the 
membrane structure and leads to pore formation.  
Chemically competent E.coli were stored at -80°C and thawed on ice for 30min. 0.5-1µg 
plasmid was added and incubated on ice for further 30min. Bacteria were heat shocked for 
30s at 42°C. The mixture was chilled on ice for 1min. 250μl super optimal broth (SOC)-
medium was added and incubated in shaking block at 350 rpm, 37°C for 60min to help 
bacteria recover from the heat shock.  
 Cultivating transformed bacteria  3.2.1.2
If absorbed plasmids harbor a gene conferring antibiotic resistance, transformed bacteria 
can be enriched by antibiotic selection. The bacterial cell suspension is grown on agar plates 
containing the respective antibiotic and only plasmid containing bacteria will have the ability 
to metabolize the drug and form colonies. Single colonies can then be picked and amplified 
in liquid cultures. All plasmids used in this study harbored an ampicillin-resistance gene. 
50-100µl of the bacteria suspension was plated on ampicillin-containing agar plates 
(100µg/ml). Plates were incubated upside down at 37°C for 12-16h. Colonies were picked by 
an autoclaved toothpick and transferred into 5ml LB medium containing 100µg 
ampicillin/ml. Bacteria were grown for 8-14h at 37°C, 190rpm. Depending on the desired 
amount of DNA, liquid cultures were either used for DNA isolation (Mini Preparation) or 
used for inoculation of 250ml ampicillin-LB medium which was then kept on the shaking 
incubator for further 12-14h and finally used for DNA isolation (Maxi Preparation). 
 Plasmid isolation  3.2.1.3
Plasmids can be isolated by alkaline lysis. Addition of an alkaline solution containing a 
detergent like Sodium dodecyl sulfate (SDS) disrupts bacterial cell membranes. The chemical 
can enter the cell and nucleic acid is denatured. A neutralizing solution like sodium acetate 
allows the renaturing of plasmid DNA, but precipitates chromosomal DNA and the 
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detergent. The plasmid can then be purified using an ion-exchange polymer column. DNA is 
bound to the column, washed and finally eluted with a saline solution. Purified DNA is then 
pelleted by isopropanol-precipitation and centrifugation and dissolved in H2O. 
Bacterial cultures were centrifuges at 6000rpm, 10min, 4°C (2ml Mini culture) or at 
4600rpm, 30min, 4°C (250ml Maxi culture) and either frozen and stored at -80°C or directly 
submitted to alkaline lysis according to the kit-manufacturers’ protocol. The following kits 
were used: 
• Mini Prep: GeneMATRIX Plasmid Miniprep DNA Purification Kit 
• Maxi Prep: Qiagen EndoFree® Plasmid Purification Kit. 
The concentrations of DNA were determined using the spectrophotometer NanoDrop® ND-
1000. Purified DNA was stored at -20°C. 
 
 Restriction digestion 3.2.1.4
DNA can be digested enzymatically using restriction endonucleases. These enzymes 
recognize particular and unique sequences of DNA and act as molecular scissors producing 
DNA fragments of distinct sizes with 5’-, 3’- (sticky) or no overhang (blunt) end. Visualization 
of these DNA fragments using agarose gel electrophoresis and ethidium bromide as an 
intercalating agent determines fragment sizes which can then be compared to theoretically 
expected ones. Fragments can be further extracted from the gel and be used in further 
cloning experiments, which needs higher amount of DNA, or the gel is used to determine 
integrity of isolated DNA samples, lower amount of DNA. 
 
reagent  amount  
DNA  1μg  
specific Enzyme buffer (10x)  2μl  
BSA (10x), if necessary  2μl  
Enzyme 5U  
H2O up to 20μl  
  
The restriction digestion was Incubated for at least 1hr in the enzyme-specific reaction 
temperature in the heating block. 
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In order to have sufficient material for further cloning steps larger amount of DNA was used 
for restriction digestion.  
 
reagent  amount  
DNA  5μg  
specific Enzyme buffer (10x)  5μl  
BSA (10x), if necessary  5μl  
Enzyme 20U  
H2O up to 50μl  
 
 
Incubation of the mixture was performed for at least 3hrs at the optimum enzyme working 
temperature. 
 
 Agarose gel electrophoresis 3.2.1.5
DNA molecules are negatively charged due to their phosphate groups. They can thereby 
move in an electrical field. The velocity of the movement depends on DNA size (correlating 
with the molecules total charge and mass) and on the constitution of the medium. In 
agarose gel electrophoresis DNA is loaded onto an agarose gel, an electrical field is applied 
and the molecules start to move through the electrical field. Agarose is a natural 
polysaccharide found in red algae. As a gel, agarose medium is porous. Its pore size depends 
on the concentration of agarose (0.8 - 2%). Smaller molecules migrate faster than bigger 
molecules because they move much easier through the pore mesh. Thus, DNA fragments can 
be separated according to their size. A DNA intercalating dye visualizes the fragments and a 
marker of known sizes determines the size of these fragments. Fragments can be extracted 
from the gel and be used in further cloning experiments or the gel is simply used to 
determine integrity of isolated DNA samples like in this work. 
Depending on the intended concentration, 0.8 – 2g of purified agarose were dissolved in 
100ml 1x TBE buffer by heating in a microwave. After a short cool down, 1 drops of 
ethidiumbromide (1mg/ml) was added and the mixture was decanted carefully into a gel 
chamber. A comb was inserted for the formation of wells and the gel was solidified and 
cooled for 20min at RT. The chamber containing the gel was placed into the electrophoresis 
tank with 1x TBE buffer. 8µl of the digested DNA samples were mixed with 2µl loading buffer 
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5x Blue Run and loaded into the gel chambers. Gel electrophoresis was performed for 45min 
at 150V. Fragment sizes were estimated by visualization under UV light and comparing DNA 
bands to a DNA ladder loading control. 
 
 Ligation of linear DNA fragments 3.2.1.6
Inserting the desired DNA fragment into a vector was performed by using T4 DNA ligase. This 
enzyme catalyzes the formation of a phosphodiester bond between the terminal 5'-
phosphate and 3'-hydroxyl groups of duplex DNA. T4 DNA ligase efficiently joins blunt and 
sticky ends and repairs single-stranded nicks in duplex DNA. The DNA fragment used for 
ligation should be at least 3-fold higher than the vector. After mixing the appropriate 
amounts of insert and vector, 2μl of reaction buffer (containing ATP), and 1μl of the ligase 
was added and the final volume was adjusted to 20μl. The reaction was started in a 
thermocycler. After incubation for 16 hrs at 16 ° C the enzyme was inactivated at 65°C for 
10min. The ligation mixture was either stored at -20°C or directly used for bacteria 
transformation.  
 
 RNA isolation from cells 3.2.1.7
Depending on the number of cells, the isolation of mRNA was performed using, RNeasy Mini 
or Micro Kit (Qiagen) according to the manufacturer's instructions. Isolated RNA was then 
stored at -80 ° C. 
RNA from murine hematopoietic stem cell populations (<106 cells) was isolated with 
PicoPure kit (Life Technologies). Cells were directly sorted into 50µl of extraction buffer 
provided by the kit. Isolation was done according to the manufacturer’s protocol and RNA 
was eluted with 12-15µl of H2O.  
 
 Photometric determination of DNA and RNA concentration  3.2.1.8
Determining the concentration of DNA was performed using the Nanodrop 
spectrophotometer. The ratio of absorbance at 260 nm and 280 nm was used to assess the 
purity of DNA and RNA. A ratio of about 1.8 is generally accepted for pure DNA and a ratio of 
2.0 is accepted as pure for RNA. If the ratio is significantly lower in either case, it may 
indicate the presence of protein, phenol or other contaminants that absorb strongly at or 
near 280 nm.  
 Material and methods 
39 
 
 Quantitative polymerase chain reaction  3.2.1.9
Quantitative polymerase chain reaction (qPCR) amplifies and simultaneously quantifies a 
targeted DNA molecule. Using specific primers and the LightCycler ® 480, a sensitive 
detection and quantification of the desired DNA sequence can be performed. The PCR 
product size should not exceed 500 bp. Using SYBR® Green, a dye which intercalates 
between double-stranded DNA, the amount of product formed by a spectrometric detection 
can be accurately determined after each cycle. The quantity of target DNA or cDNA is either 
an absolute number of copies or a relative amount when normalized to DNA input or 
additional normalizing genes.  
The qPCR was performed according to the following protocol: 
reagent  amount  
cDNA (1:10)  4µl  
Primer (forward)  1μl  
Primer (reverse) 1μl  
SYBR® Green PCR Master Mix  10µl  
H2O 4μl  
 
 Polymerase chain reaction (PCR) 3.2.1.10
PCR is a method based on using the ability of DNA polymerase to synthesize new strand of 
DNA complementary to the desired template strand. Because DNA polymerase can add a 
nucleotide only onto a preexisting 3'-OH group, it needs a primer to which it can add the first 
nucleotide. This requirement makes it possible to delineate a specific region of template 
sequence that should be amplified. At the end of the PCR reaction, the specific sequence will 
be accumulated in billions of copies (PCR amplicons). 
To perform genotyping PCR on transgenic mice, 100-500ng DNA isolated from mouse tail 
(DNeasy Blood & Tissue Kit) was used as PCR template. PCR was performed according to the 
following protocol: 
reagents amount 
DNA 100ng 
Primer Mix (10µM each) 1.5 µl 
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Before adding the Taq polymerase, the mixture was well mixed and then stored on ice until 
the start of the reaction in the thermocycler. The target sequence was amplified using the 
following program: 
 
reaction step  temperature  time  
denaturation  95°C  2 min  
denaturation  95°C  45 s  
hybridization  53° - 60°C  45 s  
elongation  72°C  30 s  
(30 cycles)  
final elongation  72°C  5 -7 min  
   
 Sequencing DNA fragment after cloning 3.2.1.11
Plasmids had to be tested for their integrity before amplification and usage in further 
experiments. DNA is replicated in vitro using a primer, a DNA polymerase, a mix of normal 
deoxynucleosidetriphosphates (dNTP) and only one type of radio-labeled dideoxynucleotides 
(ddNTP) lacking a 3’-OH group. If ddNTPs are incorporated into the newly synthesized DNA, 
replication is terminated since a new phosphodiester bond cannot be formed. These 
fragments are subsequently separated via electrophoresis and the sequence can directly be 
read from the gel picture. 
2.5µg of the DNA sample were diluted in 30µl H2O in a 1.5ml reaction tube. Sequencing was 
performed at GATC Biotech in Konstanz. Primers were chosen based on the following 
criteria: 17-28 bases in length, G/C-content of about 50-60%, location about 50bp up- or 
downstream of region to be sequenced, melting temperature preferentially 52 – 58°C and a 
G- or C-3‘end was favored. If not available, primers were also synthesized by GATC Biotech. 
Red Taq master mix(2x) 12.5µl 
H2O up to 25µl 
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 cDNA synthesis 3.2.1.12
A rapid method to analyze gene expression in cells is the amplification of RNA by PCR. 
However, since RNA cannot serve as a template for Taq polymerase, it must first be 
transcribed to DNA by reverse transcriptases (RT).  
Up to 5µg of RNA was used as template for cDNA synthesis. Oligo(dT) nucleotides which 
consist 12-18 dTs and bind specifically to the poly-A tail of eukaryotic RNA were used as 
primers. cDNA was synthesized using SuperScript® III kit according to the manufacturer’s 
protocol. 
 
 Global gene expression profiling  3.2.1.13
RNA was harvested according to section 3.2.1.7. RNA integrity was determined by the 
Aligent 2100 Bioanalyzer at the DKFZ Genomics and Proteomics Core Facility. RIN values 
ranging from 9.5 to 10 were used for gene expression profile.  
500 ng of RNA was submitted to the DKFZ Genomics and Proteomics core facility for the 
expression profile on MouseWG-6 v1.1 Expression BeadChip (IlluminaTM). 
 
 Western blot 3.2.1.14
Cells were lyzed and resuspended in RIPA buffer at 106 cells/100µl. Cell lysate was 
centrifuged at 13,000 rpm, 4°C, 10 min. The supernatant containing protein was used for 
Western blot. 15-20 μg of protein lysate was mixed with 4x loading buffer and heated at 
95°C for 6 min. The samples were centrifuged at 12000 rpm for 5 min and placed on ice. The 
first step was polyacrylamide gel electrophoresis. The stacking and resolving gels were made 
according to the protocol. APS and TEMED were added right before casting the gel. First the 
resolving gel was poured and ethanol was added gently on top of the gel. The gel was let to 
solidify and then ethanol was removed. The stacking gel was poured and the comb was 
immediately inserted. The gel was let to solidify for 20-30 min. The comb was removed the 
wells were washed with running buffer to remove any piece of remaining gel. 
Electrophoresis tank was filled with running buffer. Protein lysate samples and 10µl of 
protein ladder were loaded in wells. Gel electrophoresis was run with 120V for 90min. The 
gel was blotted with PVDF membrane with 25V for 1hr. the membrane was incubated in 
blocking buffer for 1hr at RT and then washed with washing buffer 3x, 5min each. The 
membrane was incubated with primary antibody overnight at 4°C on a roller followed by 3x 
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washing, 5min each. Secondary antibody was diluted in antibody buffer and incubated with 
the membrane for 1hr at RT and then washed 3X, 5min each. Post washing, the protein 
bands were detected by developing the membrane using 1:1 volume from A and B ECL 
solution and ChemiDoc XRS with Image Lab software.  
 
3.2.2 Cell biology methods  
 Freezing and thawing cells 3.2.2.1
In order to have back up stocks of primary cells and cell lines, they can be viably frozen and 
kept at very low temperature. Cells should be frozen in complete growth medium in the 
presence of dimethylsulfoxide (DMSO). DMSO is used as a cryoprotective agent; it allows 
slower cooling rates by reducing ice crystal formation which can damage the cells. 
To freeze the cells respective cell suspensions were centrifuged or adherent cells were 
harvested (3.2.2.3.1) and resolved in 750μl growth-medium. The cell suspension was 
transferred into a cryotube and mixed with 750μl of the respective freezing-medium diluting 
DMSO to 7.5%. Cells were placed in a freezing box filled with isopropanol providing a cooling 
rate of 1°C per min which is required for successful cryopreservation of cells. The freezing 
box was then kept at -80°C for 24-48hrs. Frozen cells were transferred to the vapor phase of 
liquid nitrogen for long-term storage. 
For thawing the cells, the respective cryotubes were placed in a 37°C water bath until only a 
small ice piece was left. Cells were transferred in a 50ml falcon tube and 1ml growth-
medium or in case of adherent cells conditioned thawing medium was added gently to thaw 
the remaining cells completely. In order to further dilute the DMSO from the freezing 
medium, another 5ml of thawing medium was gradually added during 1 minute. Finally, 
20ml medium was added to the cell suspension which was then centrifuged. Cells were then 
cultured in humidified incubator at 37°C, 5% CO2. 
 
 Determination the number of cells 3.2.2.2
The dye exclusion test is used to determine the number of viable cells present in a cell 
suspension. It is based on the principle that living cells possess intact cell membranes, 
therefore certain dyes, such as trypan blue cannot enter the cell. 
Suspended cells were mixed with trypan blue in specific dilution (1:2 – 1:100). A cover slip 
was placed on a Neubauer chamber and 10µl of the cell mixture was loaded into the 
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counting chamber. Light, viable cells were counted in 4 quadrants under a light microscope. 
The number of cells/ml in cells suspension was calculated according to this formula:  
 number of cellsml = number of cells4 quadrants x dilution factor x 104 
 
1 quadrant holds 0.1µl (= 10-4ml). The average number of cells per quadrant multiplied with 
the dilution factor gives the average number of cells per 0.1µl. In order to calculate the 
average number of cells per ml, the average number of cells per 0.1µl has to be multiplied by 
104. 
 
 Cell line and hematopoietic stem cell culture 3.2.2.3
3.2.2.3.1 Adherent cell culture  
In this work adherent HEK-293T (293T) and HeLa cells were used. 293T cells are human 
embryonic kidney cells which stably express the SV40 T-antigen. HeLa cells are adherent cells 
derived from human cervical carcinoma.  
Culturing of adherent cell lines was performed in cell culture flasks in an incubator at 
humidified atmosphere (37°C, 5% CO2). At 80% of confluency, medium was aspirated and 
the cell layer was washed with 10ml PBS. 5ml 0.025% Trypsin was added and cells were 
incubated at 37°C for 5min. The reaction was stopped by the addition of 20ml stopping 
medium. The cell suspension was centrifuged (1200rpm, 5min, 4°C) and resuspended in 5ml 
growth medium. 1/100 – 1/10 of the cell suspension was transferred into a new flask 
containing 15ml growth medium and culturing was continued at 37°C. 
 
3.2.2.3.2 Suspension cell culture 
The suspension cells used in this work comprised C1498, FDCP-Mix, WEHI-3B and 32D. 
C1498 are murine lymphoblasts suspension cells derived from C57BL/6J mouse with acute 
myeloid leukemia. FDCP-Mix cells are murine, multipotent, interleukin-3 (IL3)-dependent 
progenitor cells established from long-term bone marrow cultures. 32D cells are 
immortalized myeloblast-like cells originally derived from long-term cultures of murine bone 
marrow. WEHI-3B is a macrophage-like myelomonocytic leukemia cell line established from 
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inbred BALB/c mice. Due to the integration of a retroviral genome in the vicinity of the IL3 
gene this cell line constitutively produces IL3.  
Suspension cell cultures can be maintained by adding fresh medium or replacement of 
medium. Alternatively, cell cultures can be established by centrifugation with subsequent 
resuspension in fresh medium at 1 to 3 x 105 viable cells/mL. A saturation density of 1 to 2 X 
106 was obtainable. Depending on cell density fresh medium can be added to cell suspension 
every 2 to 3 days.  
 
3.2.2.3.3 Generating IL3 containing supernatant from WEHI cells 
WEHI cells were counted and resuspended to a final concentration of 1x106 cells/ml. Cells 
were incubated at 37°C, 5% CO2 for 24hrs. The cells were spun down at 1200 rpm, 4°C, 5min 
and the supernatant was collected and filter sterilized (0.22µm). Aliquotes of WEHI 
supernatant were stored and stored at –20°C. It was later used as IL3 source in 32D cells 
conditioned medium. 
3.2.2.3.4 Hematopoietic stem and progenitor cell culture 
Hematopoietic stem and progenitor cells were sorted from the mouse BM (3.2.2.8, single or 
bulk cells (up to 104/ well) were cultured in 96-well plate in 100 µl StemSpanTM medium 
containing 1% pen-strep, 100ng/ml rmSCF, 100ng/ml Flt3ligand, 100ng/ml rhTPO, and 
20ng/ml IL3. Cell medium was changed every third day or when the cell number reached 
105.  
3.2.2.3.4.1  LSK cell transduction 
104 LSK cells were suspended in 100 µl StemSpanTM medium containing 1% pen-strep, 
100ng/ml rmSCF, 100ng/ml Flt3ligand, 100ng/ml rhTPO, 20ng/ml IL3 and Protamine sulfate 
8µg/ml in one well of a 96-well plate. Viral particles were added to cells with MOI 60 and the 
plate was spun at 1000 rpm, 1hr, 4°C. The cells were incubated at 37°C, 5% CO2.  
   Colony forming assay (CFC) 3.2.2.4
Hematopoietic stem and progenitor cells isolated from murine BM cells can be differentiated 
in vitro using semi-solid MethoCult™ medium containing cytokines. Depending on the 
cytokines, cells can be differentiated to various blood lineages and form colonies. The type 
and number of colonies can be determined by light microscope.  
Three types of MethoCult™ semi-solid medium were used in this work. MethoCult™ M3630, 
which is optimized for the detection and quantification of mouse pre-B progenitor cells in 
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BM. MethoCult™ GF M3434 which has been formulated to support optimal growth of 
erythroid progenitors (BFU-E), granulocyte-macrophage progenitors (CFU-GM, CFU-M, CFU-
G) and multi-potential granulocyte, erythroid, macrophage, megakaryocyte progenitors 
(CFU-GEMM). MethoCult™ H4230 does not contain any cytokine and provides the basic 
medium for CFC assay. 
The MethoCult™ aliquots were thawed overnight at 4 °C or a few hours before use at RT. 
After a brief mixing of the medium, the aliquots were let stand to lose the air bubbles. To 
perform pre-B CFC, 2x105 murine total BM cells were used per dish. Cells were suspended at 
3x concentration in 300µl of IMDM+2% FBS and then added to 3ml MethoCult™ 3630. The 
mixture was briefly mixed and let stand for 2-3 min till the air bubbles disappeared. 2x 1.1ml 
of the cells and semi-sold medium mixture were distributed to 2x 3.5cm dishes in a 5ml 
syringe with a blunt end needle. To prevent the semi-solid medium drying out, 3ml H2O was 
added to another 3.5cm dish without a lid. The dishes containing cell suspension and H2O 
were placed in a 10cm dish and incubated at 37°C and 5% CO2. Colonies were observed and 
counted under light microscope after 10-12 days.  
Myeloid CFC was performed with 2.5x104 total BM cells and MethoCult™ GF M3434 
following the same procedure as pre-B CFC. 
Similar protocol was followed to perform IL3 independent CFC assay using MethoCult™ 
H4230 and 105 32D cells/dish. The colonies were counted after 10-12 days. The semi-solid 
medium was once washed with 25ml cold PBS, and washed with 10ml PBS centrifuged at 
1200rpm, 4°C, 5min 
   Lentiviral vector production 3.2.2.5
In order to stably express transgenes in primary hematopoietic stem cells and cell lines, 
lentiviral vectors (LV) encoding the respective expression cassette were produced. These 
vectors were used as a gene shuttle delivering the genetic material of interest into the target 
cells. 
6x106 293T-cells were seeded into 15cm-dishes. Cells were grown in 15ml IMDM growth 
medium for 24hrs at 37°C and 5% CO2. Medium was replaced with 13ml fresh growth 
medium. Polyethyleneimine (PEI, 179.25µg/500µl blank IMDM) was used as a transfection 
agent. PEI packs the negatively charged DNA into positively charged particles facilitating 
cellular uptake by endocytosis. 500µl plasmid-mix was prepared with IMDM. The solution 
was filter sterilized (0.22µm pore diameter) and mixed with an equal volume of PEI/IMDM. 
After 20min incubation at RT, the mixture was added into the cells and the dish was gently 
shaken in order to distribute the DNA among the cells.  
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plasmid designation function amount per dish (µg) 
101 gag-pol 12.5 
102 reverse transcriptase 6.25 
103 VSV-G 9 
transfer plasmid encoding the transgenes 32 
 
Medium was refreshed 16h after incubation (15ml). After further 48hours of incubation, 
medium containing lentiviral particles was harvested and filter sterilized (stericup vacuum 
filtration system). It was divided equally to ultracentrifugation tubes and lentiviral particles 
were pelleted at 20.000rpm, 2h, 20°C. The supernatant was discarded and tubes were put 
upside down on a piece of tissue. After 10min incubation at RT, residual medium was 
removed by a sterile cotton-tip. 50µl PBS was added to each tube, tubes were incubated at 
RT for 30min. The pellet was pipetted up and down 25 times with the PBS. The supernatants 
from all centrifuge tubes was collected in a 1.5ml-reaction tube and rotated at RT for further 
20min. The concentrated viral supernatant was aliquotted and stored at -80°C.  
   Determination of Functional Lentiviral Titers  3.2.2.6
The efficiency of lentiviral infection depends on the amount of functional and infectious viral 
particles present at the time of infection. This amount might differ depending on production 
and harvest conditions. Therefore, the amount of infectious particles in a given solution 
(functional titer) should be determined. The titer can be quantified using a serial limiting 
dilution transduction assay under standardized conditions. 
Adherent HeLa cells were grown in liquid medium according to manufacturers’ protocol in 
an incubator at humidified atmosphere (37°C, 5% CO2). At about 70-80% of confluency, 
medium was aspirated and the cell layer was washed with 10ml PBS. 5ml 0.05% Trypsin was 
added and cells were incubated at 37°C for 5min. The reaction was stopped by the addition 
of 20ml stopping medium (PBS+10% FBS). The cell suspension was centrifuged with 
1200rpm, 5min, at 4°C and either 5x104 (24hrs prior to transduction) or 105 cells (4hrs prior 
to transduction) were seeded in a 6-well plate. 
Growth medium was replaced by 500µl conditioned growth medium containing 16µg 
Polybrene/ ml. Concentrated LV was diluted in a 24-well-plate, 2µl of virus stock was added 
into 1ml growth medium and mixed properly. Five serial 1:10-dilutions were prepared by 
transferring 100µl of the previous well into 900µl fresh growth medium (dilution factor 10-3 
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to 10-7). Subsequently, 500µl of each viral dilution was added into the wells containing the 
HeLa cells in 500µl conditioned medium containing Polybrene. Transduction was allowed for 
72hrs at 37°C, 5% CO2. Then, cells were trypsinized and prepared for FACS analysis 
(3.2.2.7.1). 
The functional titer of the lentiviral stock solution was calculated with the following formula 
from the sample when 1% to 25% (y %) of all living cells were transduced: 
 LV concentration ( TU ml� )
= number of cells (time of infection)x dilution factor x y % GFP+cells100  
 
   Flow Cytometry 3.2.2.7
Flow Cytometry (fluorescence activated cell sorting, FACS) is a technology that measures 
cells or particles in liquid suspension. A flow cytometer, like the BD™ LSRII, is composed of 
three subsystems: fluidics, optics and electronics. Samples are kept in suspension and loaded 
into the cytometer’s fluidic system which brings the sample to a point of interrogation where 
it is detected by a laser beam of a certain wavelength. Because of the samples fluorescent 
properties or previous treatment of the sample with fluorescent dyes, the fluorescent 
components are excited by the laser light and emit fluorescent light which is subsequently 
modified by mirrors, a photo multiplier tube system and filters. The modified light is then 
detected by collection components of the optics subsystem. The electronic subsystem 
converts the light signal into an electronic one and digitizes the data which is then displayed 
by a computer using BD FACSDiva™ software. The experimenter can measure fluorescence 
intensity, counts, the relative complexity and the relative size of particles or cells. 
In addition to the BD™ LSR II, the BD FACS Aria™ II Cell Sorter was also used in this work. A 
cell sorter has a similar function to a common cytometer. The optics system contains 
additional features for sorting the samples according to different characteristics of choice. 
The sample drop is charged depending on the emitted fluorescence signal after excitation 
and deflected in a subsequent electrical field. Tubes at respective positions collect the sorted 
samples. 
For flow cytometric measurement or sorting of viable cells, specific fluorescent dyes can be 
used to exclude dead cells. Membrane integrity of viable cells guarantees that these dyes 
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cannot invade a cell. Cell death results in loss of membrane integrity. Thus, the stain enters 
the dead cells which can be identified by the FACS machine. 
To exclude dead cells either Fluorogold or Propidium iodide (PI) was used in this work. PI is 
excited at 488 nm and emits at a maximum wavelength of 617 nm. Fluorogold was only used 
in combination with dyes occupying the red laser (635nm). 
3.2.2.7.1 Preparation of cells for flow cytometry 
Cells were centrifuged and the pellet was washed once with 1ml PBS. Subsequently, cells 
were resuspended in 500µl PI and spun down. Samples were resuspended in 300µl PBS and 
stored on ice until FACS analysis. 
    Purification of hematopoietic stem cell populations from bone marrow 3.2.2.8
In order to isolate various hematopoietic stem and progenitor cell populations, mouse tibia, 
femur and ilium bones were harvested and flushed with 5ml syringe (0.6mm/23G needle) in 
3ml HF solution in a round bottom tube. BM cells were counted at 1:100 ratio with Türk 
solution according to previously described protocol (3.2.2.2). The blood lineages were 
depleted from the whole BM cells using EasySep™ kit. Lineage depleted cells were counted 
with Trypan blue with 1:10 ratio and incubated with blocking antibody solution at 
concentration of 107 cells/100µl for 30min at 4°C. The mixture of cells and blocking solution 
was then incubated with 10x pre-diluted respective antibody cocktail for 30min at 4°C. Post 
antibody staining, the cell suspension was washed with HF containing Fluorogold, filtered 
with 40µm cell strainer and resuspended in HF. Cells were then sorted using FACS Aria IITM 
cell sorter.  
    Cell Titer Glo assay 3.2.2.9
C1498 cells were seeded at 5x104/ml concentration. On days 1 to 4 the ATP activity level and 
cell viability was measured by CellTiter-GloTM assay.  15µl of cell suspension was pipetted in 
a 384-well plate for 30min at RT and mixed with 15µl CellTiter-GloTM reagent which was 
previously thawed and reached RT. The cell mixture was shaken for 2min and incubated at 
RT for 10min to stabilize luminescence signal. Post incubation, luminescence level was 
measured at luminometer.   
 Staining peripheral blood cells  3.2.2.10
To stain the blood cell with lymphoid and myeloid antibody cocktails, heparin- blood was 
transferred from micro cuvette to FACS tubes. Red blood cells were lysed with lysis buffer 2 x 
5 min and washed with HF. Post lysis, the cells were incubated in C16/32 blocking antibody 
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solution at 4°C for 30min, and stained with lymphoid, myeloid and isotype control cocktails 
at 4°C, for 30min. Cells were then washed with HF and stained with Fluorogold. Stained 
blood cells were resuspended in 200µl HF and measured with BD™ LSR II FACS. 
 NF-kB activity assay 3.2.2.11
5x105 293T cells were seeded in a 6-well plate and incubated for 4-5 hrs at 37°C, 5% CO2 till 
the cells attach. Cells were transfected with combinations of LRRC33, TLR4, and GFP (5µg 
each) and NF-kB-Firefly (5µg) and LacZ (2µg) plasmids according to the same protocol 
described in section 3.2.2.5. 2 days post transfection cells were stimulated with 
Lipopolysaccharides (LPS) for 24hrs and NF-kB activity level was measured using Dual-LightTM 
kit according to the manufacturer’s protocol.  
3.2.3   Mouse experiments 
The mouse strains used for the animal experiments were B6.129S1-Plcb4tm1Dwu/J, B6.SJL-
Ptprca Pepcb/BoyJ, and C57Bl/6J mice (from the Jackson Laboratory). All animal experiments 
were approved by the “Regierunspräsidium Karlsruhe” (Application number: G-160/08 and 
G-175/13). 
   Blood collection from mice 3.2.3.1
To collect the mouse blood for further analysis, the mouse was fixed in a 50ml tube with an 
open end. Its leg was shaved and the peripheral blood was collected by puncturing the 
saphenous vein with a fine needle (0.45 mm/26G) in an EDTA or heparin-coated micro 
cuvette.  
    Determination of the blood cells count  3.2.3.2
The blood cell count was performed by Advia Analyzer at Analysis Center of the Heidelberg 
University Hospital. To prepare the blood to be measured, 60µl of EDTA-blood was mixed 
with 240μl of 0.9% NaCl solution (1:5).  
    Intravenous bone marrow transplantation 3.2.3.3
Four to six hours before transplantation the mice were lethally irradiated with 950 cGy. To 
perform intravenous injection the mouse tail was heated with a red lamp. The mouse was 
fixed in a restrainer and injection of murine bone marrow cells into the tail vein (in maximum 
200μl PBS) was performed using a needle (0.45 mm/26G). All transplanted mice were fed 
with 0.5 ml of Baytril per liter in drinking water. 
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4 Results 
 
4.1 Establishment of a selection strategy for identification of novel 
candidate stem cell regulatory genes 
Major progress in the efficiency of gene transfer using integrating vectors has allowed 
achieving a number of genetically corrected hematopoietic cell clones in vivo [105, 106, 109, 
122, 123]. 
The integration of gammaretroviral vectors has an overall preference for the transcription 
start site (TSS) of genes (± 5-10 kb), and a preference for the transcribed region of genes at 
the time of infection [99]. The flanking genomic genes can therefore get activated by the 
strong enhancer and promoter sequences within the long terminal repeats (LTRs) in 
gammaretroviral vectors. Depending on the activated gene this can cause clonal selection 
and dominance up to malignant transformation. Analyzing the integration sites (IS) 
repertoire, we detected genetic loci which are highly overrepresented, indicating for a 
selective advantage of clones carrying these common vector integration sites (CIS) in vivo. 
We therefore hypothesized that significantly enriched CIS in genetically modified blood cells 
point to a regulatory function of nearby genes in post-embryonic hematopoiesis. 
To select hematopoietic candidate regulatory genes we systematically analyzed the IS 
repertoire of gene corrected peripheral blood (PB) and bone marrow (BM) cells within a 
cohort of 10 gene therapy patients with Wiskott-Aldrich-Syndrome (WAS) using linear 
amplification–mediated PCR (LAM- PCR) technique. After exclusion of genes based on 
stringent criteria, which will be described in details, we selected 12 novel candidate genes 
with hematopoietic regulatory potential. To investigate the long term clonal activity in 
clinical gene therapy patients every individual clone harboring IS close to the selected 
candidate genes was followed up in a 4-year time period. The expression of each gene in 
hematopoietic stem (HSC) and progenitor cell (HPC) populations was assessed using whole 
transcriptome datasets of well-defined hematopoietic populations. Finally, after intensive 
literature research the most novel regulatory candidate genes in hematopoiesis were 
selected (Figure 9).  
 
Results 
51 
 
 
Figure 9: An overview of sequential steps of selecting candidate stem cell regulatory genes. The CIS 
repertoire of gene therapy patients was studied to select the top candidates of hematopoietic regulatory 
genes. The hematopoiesis contribution of HSC clones which carry integrations near candidate genes was 
investigated up to 4 years. The expression of candidate genes in different HSC populations was assessed and 
after studying the literature novel genes with unknown functions in hematopoiesis were selected for further 
analysis.  
 
Using highly sensitive LAM-PCR combined with high-throughput sequencing, a total of 
12.887 unique IS in vicinity of 3.268 genes were identified. Since in this study we used the 
combined dataset from 10 WAS gene therapy patients we set the 10 IS cutoff in vicinity of 
each gene to increase the probability of selecting candidate genes from all 10 WAS patients. 
Therefore, only genes with at least 10 different IS within a 200 kb window from their TSS 
were considered (n=588). 
It has been demonstrated that the enhancer or promoter elements in LTR region of 
integrated vectors may trans-activate host genes even if they are quite distant (~ 300kb) 
[124]. In our selection procedure we narrowed this window to 50 kb to only select genes 
which were more likely to be affected by the RV integration. Thus, we chose genes with at 
least 10 IS within a 50 kb window around their TSS (n=424).   
In order to establish the selection strategy with the highest specificity, gene clusters 
harboring the same IS in their proximity were not included in the analyses.  To detect these 
gene-rich areas, UCSC genome browser (http://genome.ucsc.edu) was used. This browser 
visualized the precise location of every IS in human genome and demonstrated the genome-
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wide distribution of IS clusters and their neighboring genes along each respective 
chromosome (Figure 10). After analyzing all IS clusters and their nearby genes, only single 
genes were selected (n=32).  
 
 
Figure 10: The position of the IS and their flanking genes were observed along the chromosome. Using UCSC 
genome browser the IS cluster (green box) and the genes in their vicinity (blue box) were localized.  
Taken all together, genes excluded in this selection procedure were either genes with less 
than 10 IS in vicinity, or genes harboring at least 10 IS but in a larger 50 kb-window from 
their TSS. To increase the specificity of our selection strategy, clusters of two or more genes 
flanking the same IS were excluded. Ultimately, only single genes neighboring 10 or more IS 
in a 50 kb window from their TSS were selected for further functional analysis (Figure 11).  
 
 
Figure 11: Schematic view of genes in vicinity of IS excluded or included as candidate hematopoietic 
regulatory genes. Genes as in red were not selected as candidate genes because of a low number of IS in their 
vicinity (a), harboring IS in a window larger than 50 kb from their TSS (b) or being located in a gene-rich area (c). 
Results 
53 
 
The genes as shown in green were selected as candidate genes since they were single genes with at least 10 IS 
in a 50 kb window from their TSS (d). IS: integration site; TSS: transcription start site. 
 
Interestingly, we observed that 20 out of 32 final candidate genes were already known to be 
involved in hematopoiesis regulation which strongly validates our selection strategy. As an 
example, the 4 highest-ranked candidate genes EVI1, CCND2, LMO2 and MDS1 are well 
known as hematopoietic regulators and key factors in malignant transformation upon 
activation.  
The hematopoietic candidate regulatory gene selection procedure is summarized in Figure 
12.  
 
 
 
Figure 12: Selecting candidate hematopoietic regulatory genes by analyzing the IS repertoire. The primary list 
of all the genes neighboring IS was first refined for the genes harboring the highest number of IS (10 or more) 
in vicinity and then the genes with more than 10 IS within a 50 kb window. In the next step, only single genes 
which were not close to other genes were considered as potential candidates. The 32 selected genes had 
various functions as transcription regulators, receptors and enzymes. 68% of these genes are well-known 
hematopoietic regulators, such as EVI1, CCND2, LMO2 and MDS1. Finally, 12 novel regulatory genes were 
selected for further functional analyses.  
Detecting long term durable candidate-gene-associated clones might point to a regulatory 
role for the selected candidate genes in hematopoiesis. Therefore, the IS repertoire of PB 
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genomic DNA from 10 WAS gene therapy patients was examined 102 times within 4 years 
post bone marrow transplantation (BMT). Analyzing the over-time clonal frequency of each 
individual 32 candidate genes revealed that these clones were detectable multiple times, 15 
(Notch2) to 93 (MDS1), in a total of 102 time points (Figure 13). This long term durability can 
strengthen the possibility that these candidate genes play a role in hematopoiesis 
regulation.  
 
 
Figure 13: The distribution of 32 highly-ranked candidate genes in individual WAS patients in four years. 
Candidate genes were detectable at different time points that each patient was analyzed, demonstrating clonal 
activity of HSC clones carrying IS near candidate genes. P: gene therapy patient.  
In order to investigate the biological role of selected candidate genes in hematopoiesis, five 
out of 12 novel candidate genes were selected for further functional experiments. According 
to our selection criteria, these genes were among the highest-ranked genes. They belonged 
to various protein families with different functions. The genes selected for further validation 
and functional analyses were ZNF217, LRRC33, PLCB4, EVL, and IRF2BPL (Table 2). 
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Table 2: The 5 candidate hematopoietic regulatory genes selected for further in vitro and in vivo analyses 
candidate genes full name 
ZNF217 Zinc Finger Protein 
LRRC33 Leucine Rich Repeat33 
PLCB4 Phospho Lipase ß4 
EVL Ena-Vasp Like  
IRF2BPL Interferon regulatory factor 2 binding protein-like  
 
 
4.1.1 Assessing the contribution of candidate-gene-associated clones in hematopoiesis  
To evaluate the contribution of selected candidate genes in post-transplant hematopoiesis, 
each individual candidate gene-associated clone marked with a specific IS was monitored in 
4 years after gene therapy. Specific clones associated to ZNF217, EVL, and PLCB4 were 
detected at multiple time points between days 90 to 1655 post-transplant. IRF2BPL and 
LRRC33-associated clones were detectable up to day 1289 and 950 respectively (Figure 14).  
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Figure 14: Long term clonal activity of the candidate genes. To evaluate the hematopoietic activity of clones 
carrying IS near identified candidate genes in post-transplant hematopoiesis, their contribution to blood 
formation were monitored at different time points after transplantation. Each dot indicates a specific clone. 
Lines represent the same clones detected at different time points. 
Clones recurrently detected at several time points over 4 years might indicate for a long 
term clonal activity and their contribution in blood formation. Furthermore, at each time 
point new clones harboring IS near identified candidate genes were also detected. 
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4.1.2 Analyzing long-term multilineage contribution of hematopoietic stem and 
progenitor cells in vivo  
The selected candidate genes were hypothesized to have regulatory functions in 
hematopoiesis; therefore their high expression in any of HSC or HPC populations might 
suggest a role for these genes in hematopoiesis. So far, various marker schemes have been 
defined for sorting HSC and HPC cells. To validate the long-term engraftment, differentiation 
and self-renewal properties of isolated HSC and HPC using defined cell surface markers, 
hematopoietic populations expressing various combinations of cell surface markers were 
purified from murine BM and transplanted into lethally irradiated mice at different numbers 
(Table 3). The engraftment of transplanted cells and their contribution to hematopoiesis in 
primary and secondary recipients were assessed over time. By using the mice with the same 
genetic background but different expression of CD45 isoforms (CD45.1 or CD45.2) on their 
nucleated hematopoietic cells, the engraftment of donor-derived cells (CD45.1) can be 
distinguished from host cells (CD45.2). 
Table 3: HSC and HPC marker combinations used for isolating various hematopoietic populations  
 
Although all HSC and HPC populations were engrafted in transplanted mice, their efficiency 
and kinetics which was assessed by the chimerism of donor-derived cells, varied between 
different populations. Approximately 5 months after primary bone marrow transplantation, 
the PB of mice transplanted with HSC_1, HSC_2 and HSC_3 showed 62.7%, 43.4% and 38% 
donor-derived hematopoietic cells respectively. Transplanting 1.5-2x107 whole BM cells from 
these mice into secondary recipient mice exhibited 70% engraftment in HSC_1 and around 
11% engraftment in HSC_2 and HSC_3, which confirmed self-renewal HSC properties (Figure 
15a).  
designation population type cell surface markers 
number of 
transplanted 
cells 
HSC_1 hematopoietic stem cells CD34-CD48-CD135-CD150+LSK 560 
HSC_2 hematopoietic stem cells Lin-CD150+CD48- 600 
HSC_3 hematopoietic stem cells Lin-CD150+CD48-CD244- 500 
HPC_1 hematopoietic progenitor cells CD34+CD48+CD135+CD150- LSK 7500 
HPC_2 hematopoietic progenitor cells Lin-CD150-CD48+CD244+ 5000 
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Within one month after BMT, the PB of mice transplanted with HPC_1 and HPC_2 
populations comprised 19.75% and 16.25% of donor-derived cells respectively. 3 months 
after BMT the activity of transplanted cells decreased to 6.6% and 1.6% and no secondary 
engraftment was detected 1 month after BMT into recipient mice (Figure 15b). 
 
 
 
Figure 15: The engraftment of transplanted HSC and HPC with various combinations of stem cell markers in 
recipient mice. a) Approximately 4 months after bone marrow transplantation (BMT), HSC_1, HSC_2 and 
HSC_3 sorted populations showed 74.8, 44.1 and 15.8 percent engraftment of donor-derived hematopoietic 
cells respectively, whole BM cells of primary transplanted mice were transplanted into secondary irradiated 
mice and the self-renewal potential of the initially transplanted cells was evaluated over time (left). BM cells 
originated from HSC_1 population showed about 70% of engraftment in secondary transplanted mice whereas 
the engraftment decreased to around 11% for HSC_2 and HSC_3 in secondary transplantation (right). b) The 
activity of HPC_1 and HPC_2 sorted fractions was restricted to the first 12 weeks after transplantation (left). No 
secondary reconstitution was observed in both HPC populations 1 month after secondary transplantation 
(right). 
To show the contribution of transplanted HSC and HPC to hematopoiesis, their 
differentiation potential to lymphoid and myeloid lineages was investigated by analyzing PB 
of recipient mice. We detected multilineage reconstitution in all transplanted HSC_1, HSC_2 
and HSC_3 populations (Figure 16). Eight weeks after BMT, transplanted HSC_1 cells gave 
b 
a 
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rise to 17.5% of T-cells, 46% of B-cells, and 15% of macrophages respectively. These lineages 
retained a stable kinetics within 41 weeks after BMT, whereas the contribution of donor-
derived granulocytes decreased from 73% (week 8) to 16% (week 41).  
In 1 month after primary BMT, HPC_1 cells gave rise to 29.7% of T-cells, 56% of B-cells, 54% 
of granulocytes and 15.9% of macrophages. Since HPC_1 did not exhibit a long term activity, 
no donor-derived lymphoid and myeloid differentiation was detected 41 weeks post-
transplant (Figure 16). 
 
Figure 16: Differentiation capability of HSC_1 and HPC_1 cells into recipient mice hematopoiesis. Kinetics of 
donor-derived lymphoid cells (T cells and B-cells) and myeloid cells (granulocytes and macrophages) in the PB 
of the recipient mice over nine months. The mice were transplanted with either 1600 HSC expressing CD34-
CD48-CD135-CD150+LSK, or 6000 HPC expressing CD34+CD48+CD135+CD150-LSK on their surface. 
 
Taken all together, we observed that within all the transplanted HSC with various 
phenotypes, CD34-CD48-CD135-CD150+LSK purified HSC showed the highest multilineage 
engraftment in primary and secondary recipient mice. Moreover, as previously described, 
isolated HPC_1 population (CD34+CD48+CD135+CD150-LSK) was only active in the first 12 
weeks after BMT in the primary mice. No engraftment was observed in secondary recipients. 
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4.1.3 Evaluating the expression of candidate genes in hematopoietic stem and progenitor 
cells 
According to our initial hypothesis, selected candidate genes are involved in HSC and HPC 
regulation, thus we tested their expression in these populations. To elucidate the expression 
of candidate genes in murine HSC and HPC, global transcriptome dataset from highly 
enriched HSC, MPP (multipotent progenitor cell) 1-4 populations were analyzed (Cabezas-
Wallscheid et al. submitted).  
Interestingly, the overall RNA expression of LRRC33, in examined HSC and MPP1-4 
populations was between 7 to 79 times higher than other candidate genes.  
ZNF217 and LRRC33 showed an ascending expression pattern from HSC towards MPP4 
population. We observed a nearly 2-fold increase at their RNA expression level in MPP4 
compared to HSC.  
Unlike ZNF217 and LRRC33, PLCB4 had a descending expression pattern from HSC and MPP1 
towards MPP4. There was a 2-fold decline between the average of PLCB4 expression in HSC 
and MPP1 compared to its expression level in MPP4.  
Although EVL almost showed no expression in HSC, MPP1, MPP2 and MPP3 populations, its 
expression had a dramatic 11-fold increase in MPP4. 
Among all the candidate genes IRF2BPL was stably expressing in all of the investigated HSC 
and HPC populations (Figure 17). 
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Figure 17: RNA expression of the selected candidate genes in HSC and HPC populations. The expression of 
each candidate gene in HSC and HPC was evaluated by whole transcriptome analysis. HSC: hematopoietic stem 
cell, MPP: multipotent progenitor (Cabezas-Wallscheid et al. submitted). 
Apparently, all candidate genes were expressing at least in one of these stem and progenitor 
cell populations. 
 
4.2 Investigating the function of candidate hematopoietic regulatory genes  
To validate the involvement of selected candidate genes in hematopoiesis, various in vitro 
and in vivo assays were performed. In addition to hematopoietic cell lines, murine 
hematopoietic stem and progenitor cells were transduced with the lentiviral vectors (LV) 
encoding for the candidate genes to achieve a stable long-term expression. Following LV 
production, the function of candidate genes in cell proliferation, differentiation, cytokine 
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dependency, clonogenicity, long term multilineage reconstitution and self-renewal was 
assessed in vitro and in vivo (Figure 18).  
 
 
Figure 18: Experimental layout to investigate the role of selected candidate genes in vitro and in vivo. HSC 
and HPC populations were harvested, transduced with the LV of the candidate genes and their effect in 
hematopoiesis, such as proliferation, differentiation and self-renewal, was assessed in vitro and in vivo.  
4.2.1 Examining proliferative activity and survival of single LSK cells in vitro 
To investigate the role of selected candidate genes on proliferation and growth kinetics of 
HSC and HPC populations in vitro, we initially optimized un-manipulated LSK cell culture 
under stem cell conditions. We further analyzed and clustered the growth kinetics of 
individual LSK clones. Following optimization and analyzing the growth kinetics of single-LSK 
cell-derived clones, we performed a similar assay with mock-transduced and cyclin D2 
(CCND2) overexpressing LSK cells (as positive control). This cyclin has a critical role in 
expansion of hematopoietic cells by functioning as a regulatory subunit of cyclin dependent 
kinase (CDK) 4 or CDK6 [125].  
4.2.1.1 Evaluating growth kinetics of LSK cells cultured in vitro 
LSK (Lin- Sca-1+ cKit+) is a heterogeneous hematopoietic population comprising HSC and HPC. 
LSK cells transduced with the candidate genes and GFP control LV can be used to study the 
effect of the candidate genes on the proliferation of hematopoietic cells in vitro. First, we 
cultured un-manipulated single LSK cells under stem conditions and examined their 
proliferation kinetics in vitro. 120 individual single-cell-derived clones were purified from 
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mouse BM, cultured with stem cell cytokines and monitored for up to 90 days. The cells in 
each clone were counted every day in the first week and 2-3 times in the following weeks. 
Individual single-cell derived clones were diluted with 1:10 ratio when they grew to 105 cells. 
Growth kinetics of clones survived up to 21, 41, 63, and 90 days were analyzed and clustered 
based on the cells life span (Figure 19).  
 
 
 
  
 
Figure 19: Proliferation kinetics of single-cell-derived LSK clones. a) BM was harvested and purified for LSK 
cells. Sorted single cells were cultured in stem cell medium and counted for up to 3 months to analyze their 
a 
c 
b 
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growth kinetics in vitro. b) LSK single cell-derived clones were clustered into 4 groups based on their life span. 
c) Proliferation kinetics of the cultured clones in 90 days. All the clones showed the same kinetics in the first 10 
days of in vitro culturing; however they showed different growth patterns after 10 days. 
We observed that after initially identical growth kinetics for up to day 10 (d10), 24.2% of the 
sorted LSK clones died within 21 days, 52,5% of clones died between d21 to d41 of culture, 
8.3% died between d41 and d63, and 15% of clones survived for up to d90.  
4.2.1.2   Analyzing survival and growth kinetics of CCND2-transduced LSK cells 
Following successful optimization of LSK cell culture in vitro and analyzing the growth 
kinetics of individual clones, we performed a similar assay using CCND2-transduced LSK cells 
as positive control to test whether any alterations in cell survival and growth kinetics could 
be detected. CCND2 has shown to have a role in expansion of hematopoietic cells by 
functioning as a regulatory subunit of cyclin dependent kinase (CDK) 4 or CDK6, whose 
activity is required for cell cycle G1/S transition [125]. However, in this assay we did not 
detect any significant difference between survival rates of CCND2 overexpressing cells 
compared to GFP control cells (Figure 20). 
 
 
Figure 20: Survival of CCND2-transduced-LSK cells compared to mock transduced control. The frequency of 
dead single-cell derived LSK cells transduced with the LV encoding for CCND2 or GFP control over 3 months.  
Furthermore, CCND2 and GFP transduced LSK cells were counted over time and the growth 
kinetics were generated and clustered into different groups based on their life span. We did 
not detect any dramatic growth changes in CCND2 transduced cells compared to GFP control 
cells. 
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4.2.2 Producing functional lentiviral overexpression vectors encoding for the candidate 
genes 
To study the effect of selected candidate regulatory genes, coding sequences of EVL, 
LRRC33, PLCB4, ZNF217, and IRF2BPL were successfully cloned into a PGK-driven LV 
backbone by excision at BamH1 and SbfI restriction sites (Figure 21). Third generation LV 
particles of all vectors were produced with titers ranging from 2x107 to 8x108 transduction 
unit (TU)/ml. 
 
Figure 21: LV constructs encoding for individual candidate transgenes: pCCL-PGK-Transgene-IRES-eGFP. The 
coding sequences of five selected candidate genes were cloned into a LV backbone followed by an IRES 
sequence and eGFP as a marker gene. LTR: long terminal repeat; ψ: packaging signal; PGK: phosphoglycerate 
kinase; IRES: internal ribosomal entry site; eGFP: enhanced green fluorescent protein. 
 
The transcription and translation of the transgenes were verified by examining transduced 
cell lines. A 1.000 to 100.000-fold increase of relative mRNA expression was observed by 
performing qPCR on cDNA obtained from 293T cells transduced with multiplicity of infection 
(MOI) 10 and sorted for GFP+ cells one week after transduction. 
In addition, protein overexpression of PLCB4 and EVL, which had available antibodies, was 
detected in transduced 293T cells or hematopoietic C1498 cell (Figure 22). 
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Figure 22: Overexpression of the candidate genes in transduced cells at RNA and protein level. a) The RNA 
expression of each candidate gene in 293T transduced cells was quantified using qPCR. The expression levels 
are normalized to mock control. b) Overexpression of PLCB4 and EVL proteins in 293T and C1498 transduced 
cells.  
 
4.2.3 Studying the impact of candidate genes on hematopoiesis in vitro  
In order to address whether candidate genes function in hematopoiesis regulation, in vitro 
assays were performed to investigate proliferation, colony forming capacity and cytokine 
independency of hematopoietic cells overexpressing candidate genes. 
4.2.3.1   Studying the viability of hematopoietic cells overexpressing candidate genes  
To evaluate the effect of candidate genes’ overexpression on hematopoietic cell viability, we 
performed Cell Titer-Glo assay which is used to measure ATP activity level of cells. ATP is an 
indicator of metabolically active and viable cells [126]. ZNF217, LRCC33 and EVL transduced 
C1498 hematopoietic cells showed significant 1.9, 1.5, and 1.3-fold increase in their ATP 
level compared to GFP transduced control cells (Figure 23).  
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Figure 23: Metabolic activity of transduced hematopoietic C1498 cells. ZNF217, LRRC33 and EVL transduced 
C1498 cells show significantly higher ATP activity compared to mock control cells using Cell Titer-Glo assay. 
Therefore, C1498 cells overexpressing ZNF217, LRRC33 and EVL demonstrated increased 
viability compared to GFP control cells.  
4.2.3.2  Analyzing cytokine dependency in hematopoietic cells overexpressing candidate 
genes  
To further explore the effect of candidate genes on the proliferation of hematopoietic cells, 
interleukin 3 (IL3)-dependent mouse FDCP-Mix progenitor cells were transduced with the 
LVs encoding for the candidate genes and cultured in the medium containing IL3. Moreover, 
to test whether the candidate genes overexpression can transform hematopoietic cells, 
transduced FDCP-Mix cells were cultured in the absence of IL3. The growth kinetics of 
transduced cells were evaluated over time.  
We observed that cells transduced with ZNF217, IRF2BPL and c-Myc showed increased 
proliferation when cultured with IL3. Remarkably, ZNF217, IRF2BPL and c-Myc transduced 
FDCP-Mix cells survived and proliferated in IL3 free medium for 2 up to weeks (Figure 24).  
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Figure 24: Growth kinetics of FDCP-Mix cells transduced with the LV of candidate genes in the presence (left) 
or absence (right) of IL3. In addition to c-Myc transduced cells, cells transduced with ZNF217 show higher 
growth rate in presence of IL3. ZNF217 transduced cells show higher survival rate compared to mock 
transduced cells when cultured in IL3- medium. 
To examine whether overexpression of the selected candidate genes induces cytokine 
independency in another cytokine dependent cell line, IL3 dependent hematopoietic 32D 
c 
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cells were transduced with the LV of the candidate genes and colony forming assay (CFC) 
was performed in semisolid medium lacking IL3.  
It has been shown that 32D cells undergo cell cycle arrest and apoptosis when cultured in 
the absence of IL3 [127]. Moreover, IL3 dependent cells overexpressing c-Myc, a known 
proto-oncogene- acquire  the ability to survive and form colonies in IL3-free medium[128]. 
Therefore, in this assay c-Myc overexpressing cells were used as positive control. We 
observed that in addition to c-Myc, ZNF217 transduced cells formed a significant higher 
number of IL3 independent colonies compared to GFP transduced cells.  However, cells 
overexpressing all other candidate genes did not survive in the absence of IL3 (Figure 25).  
 
Figure 25: CFC assay on transduced 32D cells transuded with the LV of four candidate genes in absence of IL3 
cytokine. Hematopoietic 32D cells were transduced with LV of ZNF217, LRRC33, IRF2BPL, and EVL candidate 
genes and cultured in semisolid medium in the absence of IL3 cytokine. The number of colonies was counted 
after 20 days. 
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Furthermore, the percentage of ZNF217-transduced cells increased from 33% to 93% before 
and 28 days after culturing the transduced cells in the absence of IL3 respectively. The 
enrichment for ZNF217 overexpressing cells indicated that only these cells could survive and 
proliferate without IL3 (Figure 26b). Comparing the morphology of ZNF217 colonies with c-
Myc colonies by fluorescent microscope showed that ZNF217-transduced 32D cells form 
larger and more scattered colonies (Figure 26c). 
 
 
 
Figure 26: c-Myc and ZNF217 colonies in cytokine free CFC assay. a) c-Myc and ZNF217-IL3 independent 
colonies. b) CFC plates were washed and the percentage of GFP+ cells were measured and compared to the 
initial GFP. c) ZNF217 colonies showed different density and size of colonies compared to positive control c-
Myc. 
In brief, we observed that ZNF217 overexpressing hematopoietic cells show higher proliferation rate. 
Moreover, IL3 dependent cells acquired the ability to survive, grow and form colonies in the absence 
of IL3 when overexpressing ZNF217.   
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4.2.3.3 Assessing gene expression profiling of ZNF217-transduced cells  
ZNF217 is known to be a transcription regulator. To gain a better understanding of up or 
down regulated cellular pathways and ZNF217 target genes in hematopoietic cells, we 
performed a global expression profiling on hematopoietic 32D cells transduced with ZNF217 
or GFP control vector. We observed that the number of downregulated genes (n=337) was 4 
times more than upregulated genes (n=85) in ZNF217 overexpressing cells compared to 
control cells (Figure 27).  
 
Figure 27: Global gene expression profiling of hematopoietic 32D cells overexpressing ZNF217. Up (red) and 
down (green) regulated genes in ZNF217 and GFP transduced cells. 
Using Ingenuity Pathway Analysis (IPA) software the most prominent deregulated pathways 
in ZNF217 overexpressing cells were detected by categorizing deregulated genes based on 
their biological functions. The top deregulated networks in ZNF217 overexpressing cells were 
identified by associating up and downregulated genes to biological functions. The networks 
with the highest scores were involved in cancer, cellular movement, inflammatory response 
and immune cell trafficking (Figure 28). 
 
Figure 28: Top deregulated biological networks identified in ZNF217 overexpressing cells.  
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Moreover, based on IPA classification, deregulated genes were evaluated in 3 different 
categories: molecular and cellular functions, physiological system development, and diseases 
and disorders. The contribution of each deregulated pathway in its respective category was 
determined according to the total number of detected deregulated genes involved in that 
pathway. In the category of molecular and cellular functions, the highest number of 
deregulated genes played roles in cell death and survival (24.3%). In physiological system 
development category most of the deregulated genes had functions in hematological system 
development (29.8%). In diseases and disorders category, genes involved in immunological 
diseases had the highest contribution among all other deregulated genes (Figure 29). 
  
Figure 29: Categories and subcategories of ZNF217 deregulated genes. Using IPA software, up or down 
regulated genes in ZNF217 overexpressing cells were detected and classified into several groups based on their 
biological functions. IPA: Ingenuity Pathway Analysis. 
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4.2.3.4 Evaluating the role of EVL in colony forming activity  
We previously demonstrated that EVL overexpressing C1498 hematopoietic cells have higher 
ATP metabolic activity (section 4.2.3.1). To examine the colony forming ability of these cells 
we performed a soft agar CFC assay. C1498 hematopoietic cells were transduced with LV 
encoding for EVL. GFP+ cells were sorted and cells were plated at 50, 100, and 250 cells per 
dish. The number of colonies was counted 20 days after plating. EVL transduced cells formed 
2-fold higher number of colonies compared to GFP transduced cells when 250 cells/dish 
were seeded (Figure 30). 
 
 
Figure 30: CFC assay with transduced C1498 hematopoietic cells overexpressing EVL. After transducing and 
purifying GFP+, C1498 cells, CFC assay was performed plating different number of cells in soft agar. 
Therefore by performing this CFC assay we observed that C1498 cells overexpressing EVL 
showed higher clonogenicity ability in comparison with GFP control cells.  
4.2.3.5    Analyzing the impact of  LRRC33 on NF-kB activity 
LRRC33 protein structure resembles toll-like receptor (TLR) protein family members [129, 
130]. TLR4 is one of the toll-like receptors which plays a critical role in the activation of 
innate immunity and NF-kb pathway [131]. Therefore, we tested whether LRRC33 can 
function as a TLR4 co-receptor and affect NF-kB activity in cells stimulated with 
lipopolysaccharides (LPS). 
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To validate the TLR-mediated inhibitory effect of murine LRRC33 on NF-kB activity, 293T cells 
were co-transfected with various combinations of LRRC33, GFP and TLR4 constructs together 
with both LacZ and NF-kB firefly luciferase reporter plasmids. The plasmids used to transfect 
293T cells were either one of LRRC33, GFP or TLR4 or the combination of LRRC33 and TLR4 
or GFP and TLR4. NF-kB activity level of cells was determined 16 hours after LPS stimulation.  
We observed that NF-kB activity decreases in LPS-stimulated cells expressing both LRRC33 
and TLR4 in comparison with the same transfected cells which are not treated with LPS and 
also mock control cells transfected with both GFP and TLR4 constructs in either presence or 
absence of LPS (Figure 31).  
 
 
Figure 31: NF-kB activity in transfected 293T cells. 293T cells were transfected with LRRC33, GFP, TLR4 or co-
transfected with LRRC33 and TLR4 or GFP and TLR4. Cells were stimulated with LPS 2 days after transfection 
and NF-kB activity level was measured.  
Therefore we detected an inhibition of NF-kB activity in cells transfected with both LRRC33 
and TLR4 vectors after LPS stimulation.  
4.2.4. Investigating the function of candidate regulatory genes in vivo 
To investigate the role of the candidate genes on hematopoiesis in vivo, LSK cells were 
transduced with LV encoding for the candidate genes and 1000 cells were transplanted into 
lethally irradiated recipient mice the day after transduction. PB from transplanted mice were 
collected and examined monthly for evaluating the donor-derived multilineage engraftment 
(Figure 32a).  
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LSK cells were transduced with the LVs of EVL, LRRC33, IRF2BPL, ZNF217, c-Myc and GFP 
with the transduction efficiency of 1.9%, 36.7%, 1.5%, 0.1%, 5.5%, and 19.6% respectively 
(Figure 32b). Donor-derived hematopoietic cells comprised about 40% of PB cells 31 weeks 
post- transplant (Figure 32c).  
 
 
 
 
 
 
Figure 32: Investigating the function of the candidate genes in vivo. a) LSK cells were sorted from BL6 mice BM 
(CD45.1), transduced with the LV of the candidate genes and transplanted into lethally irradiated recipient 
mice. The effect of the candidate genes in hematopoiesis of transplanted mice was studied by analyzing the 
mice PB over time. b) Transduction efficiency of transduced LSK cells with various LV of candidate genes. c) 
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Engraftment of the transplanted cells into primary recipient mice over 8 months (left), donor-derived GFP+ cells 
in PB of transplanted mice (right). 
In total EVL, ZNF217, IRF2BPL and GFP-transduced LSK cells were transplanted into 4 mice 
each and LRRC33 and c-Myc transduced LSK cells were transplanted into 5 mice each.  
 
Figure 33 : Number of mice transplanted and engrafted with transduced LSK cells. Of all the primary recipient 
mice 3 out of 5 LRRC33, 2 out of 5 c-Myc and 1 out of 4 GFP mice showed GFP+ cells in their PB. After secondary 
transplantation, 2 out of 7 LRRC33 and 1 out of 3 GFP mice showed > 1% GFP+ engrafted cells in PB samples. 
After examining the mice PB 3/5, 2/5, and 1/4 of primary recipient mice transplanted with 
LRRC33, c-Myc and GFP-transduced LSK cells respectively exhibited engraftment of GFP+ 
donor-derived cells (Figure 33). We observed that mice transplanted with EVL, ZNF217, and 
IRF2BPL-transduced LSK cells did not show an efficient GFP+ donor cell engraftment which 
was due to the initial low transduction efficiency. The hematopoietic multilineage 
engraftment of mice with efficient GFP+-donor-derived cell engraftment (LRRC33 and GFP 
control) was evaluated in primary and secondary mice.  
 Analyzing hematopoiesis in mice transplanted with LRRC33-transduced LSK cells 4.2.4.1
According to preliminary serial transplantation results, primary recipient mice transplanted 
with LRRC33 and GFP-transduced LSK cells respectively showed 5% and 12% of donor-
derived GFP expressing cells in their PB at week 36 post BMT. At weeks 31 and 36, the ratio 
of GFP+ T-cells was about 2-fold reduced in LRRC33 transplanted mice compared to GFP 
control mice. In contrast, the ratio of GFP+ macrophages was 2 and 5 fold increased in 
LRRC33 transplanted mice compared to GFP control vector transplants at weeks 31 and 36, 
respectively (Figure 34).  
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Figure 34: Multilineage engraftment in primary LRRC33 and control GFP transplants. Ratio of GFP+ donor-
derived peripheral T- cells (CD45.1+ CD3+), B-cells (CD45.1+ CD3+), macrophages (CD45.1+ CD11b+), granulocytes 
(CD45.1+ Gr1+) and Erythroides (CD45.1+ Ter119+) 4 – 36 weeks after BM transplants into primary recipients.  
 
At week 36 whole BM from LRRC33 and GFP primary mice was harvested and 8x106 cells 
were transplanted into each secondary recipient mouse, 16 weeks after BMT 4% to 36% of 
GFP+ cells were detected in mouse PB. Comparable to primary recipients, T-cells were 2 to 3 
fold reduced in LRRC33 transplanted secondary recipients compared to GFP control mice, 
whereas the ratio of GFP+ macrophages was 6 to 12-fold increased in LRRC33 transplanted 
mice at weeks 6 to 16 after BMT (Figure 35).  
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Figure 35: Multilineage engraftment in secondary LRRC33 and control GFP transplants. Ratio of GFP+ donor-derived 
peripheral T- cells (CD45.1+ CD3+), and macrophages (CD45.1+ CD11b+) 6 - 20 weeks post transplants into secondary recipients.  
Taken together, we observed that LRRC33-overexpressing LSK cells show higher 
differentiation towards macrophages and lower differentiation towards T-cells compared to 
control-transduced cells in primary and secondary transplants. 
 Characterizing BM cells from PLCB4 knockout mice in vitro and in vivo 4.2.4.2
Comparing the expression of the candidate gene PLCB4 in five HSC and HPC populations, we 
observed that PLCB4 had the highest expression level in HSC and MPP1 populations which 
may indicate for its critical role in these populations (section 4.1.2). Therefore, knocking 
down the expression of PLCB4 in hematopoietic stem cell populations might have effects on 
hematopoiesis process.  
PLCB4 knockout (KO) mice were already generated [132], but never reported for any changes 
in their hematopoietic system. Due to the disruption of the catalytic domain in an exon of 
PLCB4 gene, there is no PLCB4 protein expression in KO mice (Figure 36a). To understand the 
role of PLCB4 in hematopoiesis, we analyzed the BM from PLCB4 KO mice in comparison 
with wild type and heterozygote mice in vitro and in vivo.  
Compared to wild type (+/+) and heterozygote (+/-) mice, PLCB4 knockout (-/-) mice show 
lower body weight +/- (Figure 36b). Furthermore, we observed that breeding +/- mice leads 
to about 11% of 21-day old -/- progenies which is 14% less than expected according to the 
mendelian ratio of about 25% (Figure 36c).  
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Figure 36: PLCB4 knockout mice. a) No PLCB4 protein expression is detected in KO mice. b) -/- mice show a 
reduced body size compared to +/- and +/+ mice. c) Breeding +/- mice leads to lower rate of mutant 21-day old 
mice.  
 
4.2.4.2.1 Examining BM cells from  PLCB4 knockout mice in pre-B cell CFC assay 
Analyzing whole BM of -/-, +/- and +/+ at different ages revealed a 2-fold decrease in the LSK 
population from 0.2% in +/+ and +/- to 0.08% in -/- 18 and 25-day old mice. However, no 
reduction was detected in 40-day old mice (Figure 37). 
 
Results 
80 
 
 
Figure 37: Analyzing LSK population in BM from PLCB4 mice. a) 18-day old -/- mice showed a 2 fold reduction 
in the LSK cells in their BM compared to +/- and +/+ PLCB4 mice. B) No significant difference was observed 
between -/-, +/- and +/+ 40-day old mice. -/- : knockout; +/-: heterozygote; +/+: wild type PLCB4 mice. 
To test the potential of hematopoietic cells from PLCB4 mutant mice in forming preB 
colonies, preB-cell CFC assay was performed with BM cells from 18-day old mice. It was 
shown that there is a 2 and 3-fold reduction in the number of B-cell colonies in -/- vs. +/- , 
and -/- vs. +/+ mice respectively. Similarly B-cell colonies from 25-day old -/- mice were 
about 2 folds less than colonies from +/- mice. However, no significant difference was 
observed in B-cell colony count in 40-day old mice (Figure 38). 
Unlike pre-B CFC assay, myeloid colonies detected in myeloid CFC assay did not exhibit any 
significant differences in the number and type of various myeloid colonies in -/-, +/- and +/+ 
PLCB4 mice (Figure 38). 
Results 
81 
 
 
 
 
Figure 38: Myeloid and B-cell CFC assay with the whole BM cells from -/-, +/- and +/+ PLCB4 mice at different 
ages. Whole BM cells derived from -/-, +/- and +/+ PLCB4 mice at ages of 18 days, 25 days and 40 days were 
seeded in pre-B cell or myeloid semisolid medium and the number of colonies was counted 10 days later. In 
CFC myeloid assay, the type of colonies was also determined. -/- : knockout; +/-: heterozygote; +/+: wild type 
PLCB4 mice. 
  
Results 
82 
 
4.2.4.2.2 Investigating multilineage engraftment of BM cells from PLCB4 knockout 
mice 
To investigate how PLCB4 BM cells contribute to hematopoietic lineages differentiation  in 
vivo, 106 BM cells from each of -/-, +/- and +/+ mice were mixed with 105 BM carrier cells and 
injected into the tail vein of lethally irradiated mice expressing CD45.1 on their 
hematopoietic cells. Transplanted mice were bled every month and the chimerism of donor-
derived cells and rate of hematopoietic lineages differentiated from donor-derived cells 
were examined for up to 6 months (Figure 39).  
 
 
Figure 39: Transplantation of BM cells obtained from -/-, +/- and +/+ 40-day old PLCB4 mice into lethally 
irradiated recipients. Whole BM cells were harvested from -/-, +/- and +/+ PLCB4 mice, 106 BM CD45.2 cells 
from PLCB4 mice and 105 CD45.1 carrier wBM cells were transplanted into lethally irradiated CD45.1 recipient 
mice. The chimerism of donor-derived cells in the transplanted mice PB and their contribution in hematopoiesis 
was followed up every 4 weeks. -/- : knockout; +/-: heterozygote; +/+: wild type PLCB4 mice. 
107 BM cells from 40 day-old -/-, +/- and +/+ PLCB4 mice were transplanted into irradiated 
recipients to evaluate multilineage engraftment and self-renewal capacity of these cells 
during serial transplantation. We detected no significant difference in long term multilineage 
reconstitution in the primary recipients 6 months after BMT (Figure 40). 
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Figure 40: Long-term multilineage reconstitution of transplanted PLCB4-knockout BM cells in primary 
recipient mice. Long term engraftment and hematopoietic differentiation of BM cells from PLCB4 -/- mice 
compared to BM cells from +/- and +/+ was evaluated in primary transplanted mice in 6 months. -/- : knockout; 
+/-: heterozygote; +/+: wild type PLCB4 mice. 
 
In summary, analyzing BM cells from PLCB4 KO mice at different ages in vitro revealed 
distinct differences in the frequency of LSK and pre-B colony forming cells in 18 day old mice 
which were not observed in 40-day old mice.  
Moreover, we performed in vivo analysis by transplanting BM cells from 40-day old PLCB4 -/-
, +/- and +/+ mice into lethally irradiated recipients. We did not detect a significant 
alteration in the engraftment rate and differentiation to multiple hematopoietic lymphoid 
and myeloid lineages in the primary transplants.  
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5. Discussion 
5.1. The integration site repertoire from gene therapy patients can be used 
for selecting candidate hematopoietic regulatory genes 
In this study we established a strategy for selecting novel hematopoietic regulatory 
candidate genes based on systematically investigating the genome-wide retroviral vector 
(RV) integration site (IS) repertoire obtained from 10 gene therapy patients with Wiskott 
Aldrich Syndrome (WAS). The IS repertoire in gene therapy patients is usually analyzed to 
monitor the clonal dynamics after gene therapy and to detect clonal selection in individual 
patients. We hypothesized that re-analysis of this unique dataset can reveal candidate genes 
involved in the regulation of hematopoiesis.  
The IS repertoires of WAS and other diseases such as X-linked severe combined 
immunodeficiency (X-SCID) and X-linked chronic granulomatous disease (X-CGD) treated 
with retroviral vectors (RV) have so far been studied. These studies assessed the vector-
associated clonal genotoxicity, common integration sites and in vivo selection [108, 133-
136]. All these investigations showed that a clustering of IS in certain genomic loci was 
detectable, and possibly provided a selective advantage for the affected cell clones. 
Moreover, it was indicated that RV integrate into genomic DNA in a non-random pattern and 
with a preference for active genes and regulatory regions [100, 137]. 
To identify the novel hematopoietic regulators among 3.268 genes which were annotated in 
vicinity of IS, we analyzed the IS from all 10 WAS gene therapy patients in detail. We strictly 
selected single genes harboring 10 or more than 10 IS in a 50 kb window from their 
transcription start site (TSS). Moreover, we showed that clones associated to 32 selected 
genes were durable in a 4-year time period after gene therapy. By tracing each individual 
clone marked with a unique IS, we detected some clones at multiple time points within 4 
years indicating their long term clonal activity and highlighting their role as potential 
hematopoietic stem cell regulators. 
Our group previously analyzed IS repertoire from WAS patients to evaluate the long-term 
efficacy and genotoxicity of RV used in WAS gene therapy trial [97]. Studying the RV 
integration pattern from each individual patient, they identified the genes with the highest 
number of IS in a 200 kb window from their TSS [97]. However, by analyzing the combined 
dataset from all patients, we set the 10 IS cutoff in vicinity of each gene to increase the 
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probability of selecting candidate genes from all 10 WAS patients. Moreover, in other studies 
all the IS located in a 200 kb window from the TSS of neighboring genes were included in the 
analyses [136, 138]. It is known that the long tandem repeats (LTR) region of RV can impact 
the expression of neighboring genes which can be quite distant (e.g. 300 kb) due to its strong 
internal enhancer and promoter [124]. However, TSS of genes such as CCND2, LMO2 and 
EVI1 which were shown to become biologically activated after bone marrow transplantation 
(BMT) were located within a 50 kb window from IS [97], therefore in our analysis we 
restricted the distance between IS and TSS to 50 kb to increase the probability of selecting 
genes which were more likely to get transcriptionally activated.  
Furthermore, we observed that some of the IS clusters showed frequent and close 
occurrence to multiple genes. Therefore, to increase specificity on the expense of sensitivity, 
we only selected single genes which were not located in gene-rich areas. In previous studies 
the IS repertoire of RV was screened to investigate the clonal dynamics and not to select the 
hematopoietic candidate genes with possible regulatory effects on hematopoiesis.  
Constitutively activated genes in vicinity of RV integrations can cause adverse effects after 
BMT [124]. It was observed that years after BMT in WAS patients, clones carrying the IS in 
vicinity of specific genes such as LMO2 and MDS1/EVI1 became dominant over other clones 
due to insertional mutagenesis. Activation of LMO2, which is one of the most frequently 
detected loci, leads to T-cell acute lymphoblastic leukemia (T-ALL). MDS1/EVI1 activation is 
involved in the development of acute myeloid leukemia (AML) [107, 115, 136, 139, 140]. 
However, besides clones with activated LMO2 or MDS1/EVI1 and more recently MN1 [97], 
we do not have evidence for malignant transformation of other clones.  
A strong validation for our established selection strategy was detecting 20 out of 32 genes, 
such as MEIS1, CCND3, FLI1, XBP1, and FOXO1, which were previously known to have 
function in hematopoiesis regulation [141-149]. To have a wide range of genes covering 
various cellular functions, 5 out of 12 novel highly-ranked candidate genes (ZNF217, LRRC33, 
EVL, IRF2BPL, and PLCB4) from different protein families were selected for further functional 
analyses. Interestingly, ZNF217, PLCB4 and IRF2BPL were also reported in the IS analysis of X-
SCID gene therapy trial [136].  
Since the WAS gene therapy patients and patients from other gene therapy trials are still 
being followed up by analyzing their RV integration pattern over time, the systematic 
selection strategy that we successfully established in this thesis can be used to identify the 
novel hematopoietic regulatory genes in meta-datasets from a larger IS repertoire 
containing the most recent detected IS.  
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5.2. Evaluation of the candidate genes’ expression in defined hematopoietic 
stem and progenitor cell populations  
5.2.1. Efficient purification of hematopoietic stem cell population using CD34-CD48-CD135-
CD150+LSK surface markers  
The expression of pre-selected candidate genes in murine hematopoietic stem and 
progenitor cells (HSC and HPC) populations might point to their regulatory role in 
hematopoiesis. In order to evaluate the expression of selected candidate genes in these 
populations, obtaining highly purified HSC and HPC is necessary. So far, various combinations 
of cell surface markers for isolating these cells have been described [3, 31, 38, 39, 150, 151]. 
To obtain highly enriched populations, we examined different combinations of cell surface 
markers and functionally determined their purity in BMT experiments.  
All examined phenotypes of HSC showed long term hematopoietic activity in primary and 
secondary recipients. However, by transplanting the same number of cells, CD34-CD48-
CD135-CD150+LSK bone marrow (BM) cells exhibited higher hematopoietic multilineage 
engraftment in primary recipient mice and an efficient activity of donor-derived cells during 
serial transplantation. Our results showed the same multilineage donor-derived 
reconstitution for CD34-CD48-CD135-CD150+LSK population which was observed in other 
studies [6, 39]. Therefore this phenotype of HSC can be further studied for the expression of 
the selected candidate genes. 
5.2.1.1. All five candidate genes are expressed at least in one of hematopoietic stem 
an progenitor cell populations 
We asked whether the selected candidate genes are involved in HSC and HPC regulation, 
thus we tested their expression in HSC and HPC populations kindly provided by Dr. Trumpp 
(Cabezas-Wallscheid et al. submitted). Since different MPP populations have been shown to 
be either lymphoid or myeloid biased [6, 38, 152], high expression level or a significant 
change in any of these populations might indicate an important role for the candidate genes 
in the respective HSC or HPC populations. 
ZNF217, one of the candidate genes, showed lower expression in HSC. Its expression level 
increased towards more mature MPP which might suggest for its more significant roles in 
these hematopoietic progenitor cells (MPP3 and MPP4).  
ZNF217 was demonstrated that ZNF217 functions as a transcriptional repressor that 
associates with a core group of proteins including the co-repressors C-terminal binding 
protein (CtBP1) and CoREST (corepressor with REST, RE1 silencing transcription factor)[153]. 
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Banck et al. suggested that ZNF217 assembles a distinct set of histone modifying proteins at 
target DNA sites that act synergistically in transcriptional repression [154-157]. Vendrell et 
al. reported a prognostic value of ZNF217 mRNA expression levels in numerous independent 
breast cancer cohorts [158]. 
DNA amplifications regions are often sites of oncogenes that give proliferative or survival 
advantages in cells harboring these amplifications in their genome. Amplifications involving 
20q13 region encoding for ZNF217 in human are detected in a number of different cancer 
types, such as breast, ovarian, and squamous cell cancers [159, 160] [161-163]. The 
amplification of ZNF217 has been shown to correlate with tumor size in gastric cancer [164, 
165]. However, ZNF217 was never studied for its impact on hematopoiesis regulation. 
 
Interestingly, the overall RNA expression of LRRC33, the second candidate gene, in examined 
HSC and MPP1-4 populations was between 7 to 79 times higher than other candidate genes 
and in the same range of Oaz1 and Sdha housekeeping genes. This could indicate a 
substantial role for LRRC33 in HSC and HPC. In addition, LRRC33 expression increased 
towards MPP3 and MPP4 which might suggest its prominent function in more differentiated 
hematopoietic progenitor cells. Liu et al. examined LRRC33 RNA expression in different 
mouse tissues and organs. They observed that LRRC33 was highly expressed in bone 
marrow, thymus, liver, lung, intestine, and spleen. These results could suggest that LRRC33 
might play a role in the development and maintenance of homeostasis of these organs [130]. 
EVL expression in transcriptome analyses of different HSC and MPP populations showed 
almost no RNA expression in HSC, MPP1, MPP2 and MPP3 while it exhibited a drastic 11-fold 
increase in MPP4. MPP4 was already shown to be functionally lymphoid-biased [6, 166]. In 
addition, it was indicated that the average expression of EVL in mouse lymphoid lineages is 
14.5 fold higher than myeloid lineages [167]. Therefore, EVL might have an effect on MPP4 
differentiation towards B- and T-cells.  
Human EVL is a member of ENA/VASP protein family and is involved in the process of actin 
remodeling [168]. Actin regulatory proteins have a major function in neuronal migration. 
Ena/VASP proteins bind actin and control the assembly of F-actin networks by disturbing the 
function of capping proteins and bundling actin filaments. They are necessary for formation 
of filopodia in various cell types such as fibroblasts and neuronal growth cones [169-172]. It 
is reported that EVL also plays a role in homologous recombination. Therefore, EVL can have 
a dual function in actin remodeling in cytoplasm and homologous recombination in nucleus 
[173]. Despite all these findings on EVL function, its role in hematopoiesis is yet to be 
studied. 
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We observed that PLCB4 was the only candidate gene with a descending expression pattern 
from long term HSC towards more mature HPC populations. Interestingly, PLCB4 RNA 
expression in human BM and cord blood from healthy donors exhibited the same pattern 
(Simon Raffel, personal communication). This might imply that PLCB4 plays a regulatory role 
in long term HSC. Beside its abundant expression in retina, PLCB4 has been shown to be 
mainly expressed in several limited regions in central nervous system including Purkinje cells 
[174]. Although the expression of PLCB4 in neural stem cells was not specifically studied, it 
was shown that in the developing mouse brain at embryonic stages PLCB4 express in areas 
which produce the most neurons and microglia [175]. Moreover, PLCB4 expression level 
decreased when myoblasts were differentiated towards myotubes in vitro [176]. This 
indicates that PLCB4 might play a role in other types of stem cells as well as HSC. Besides 
normal cells, PLCB4 expression has been shown to have a 4-fold increase in leukemic stem 
cell (LSC) compared to non-LSC fraction (Simon Raffel, personal communication).  
PLCB4 protein is one of the phospholipase C (PLC) enzymes which hydrolyzes the inner 
membrane component of phosphatidylinositol-4, 5-bisphosphate (PIP2) and generate the 
second messengers inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 binds to 
IP3-specific receptors and causes the release of intracellular Ca2+. DAG remains associated to 
the membrane and activates protein kinase C with increasing Ca2+ level [177]. This procedure 
leads to the regulation of numerous physiological processes such as muscle contraction 
[178], chemotaxis [179], opioid sensitivity [180] and cell proliferation and survival [181, 182]. 
However, the role of PLCB4 in hematopoiesis was never reported. 
The fifth candidate gene, IRF2BPL, reveals a steady level of RNA expression in all HSC and 
HPC indicating that its expression is not specific to any of these populations. However, since 
the expression amount is considerable the role of IRF2BPL in hematopoiesis regulation 
should be further studied.  
Less than 5% of human genes are intronless, IRF2BPL is also an intronless gene and does not 
need posttranscriptional splicing; therefore it can be efficiently transcribed with higher level 
of protein expression. Furthermore, intronless genes are not likely to undergo aberrant 
splicing, thus leading to greater transcriptional fidelity [183]. It is demonstrated that this 
gene is a transcriptional factor which functions within neuronal networks of the 
neuroendocrine brain and is required for the appropriate initiation of female puberty and 
maintenance of female reproductive cyclicity. Based on these findings, this gene was also 
designated as enhanced at puberty 1 (EAP1) [184]. However, the role of IRF2BPL in 
hematopoiesis and blood formation process was never addressed before. 
In brief, all candidate genes are expressed at least in one of the examined HSC and HPC 
populations which might point to their importance in hematopoiesis. Performing in vitro and 
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in vivo analyses will allow gaining a better understanding to the biological function of the 
selected candidate genes.  
5.3. Investigating the role of candidate genes in vitro and in vivo 
5.3.1.  Single LSK (Lin- Sca-1+c-Kit+) cells show different growth kinetics under stem cell 
condition in vitro 
To investigate the role of selected candidate genes on proliferation and growth kinetics of 
HSC and HPC populations in vitro, we first cultured un-manipulated single LSK-cell-derived 
clones under stem cell conditions in vitro. We observed that all living single-cell derived 
clones showed the same growth kinetics in the first 10 days. These cells started exhibiting 
different proliferation kinetics in a period between day 10 and day 90. We categorized the 
clones into 4 groups based on their life span and proliferation kinetics. This is due to the 
heterogeneity of LSK population comprising long and short term repopulating hematopoietic 
stem cells [39]. Although all mouse HSC and HPC appear to have the Lin- Sca1+ c-Kit+ 
phenotype, all cells with this phenotype are not HSC or HPC [185, 186]. Some cells only 
provide short-term hematopoietic repopulation and some have no demonstrable stem cell 
activity [187].  
After optimizing single LSK cell culture in vitro, we aimed to know if single-LSK cell-derived 
colonies overexpressing selected candidate genes could be used as an appropriate model to 
detect candidate genes induced changes in survival and proliferation. We first performed the 
experiment using cyclin D2 (CCND2), as a positive control. This cyclin has a critical role in 
expansion of hematopoietic cells by functioning as a regulatory subunit of cyclin dependent 
kinase (CDK) 4 or CDK6, whose activity is required for cell cycle G1/S transition [125]. We 
observed that the proliferation kinetics of CCND2-transduced LSK cells did not show a 
significant difference compared to their mock counterpart. Although transduced-single LSK 
cells were successfully cultured in vitro, this model does not seem to be appropriate to 
assess the impact of transgenes on proliferation and growth kinetics. This might be due to 
the unstable expression of CCND2 in the initially transduced cells.   
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5.3.2. ZNF217 overexpression increased survival and proliferation of hematopoietic cells 
in vitro 
5.3.2.1. Hematopoietic cells overexpressing ZNF217 show increased growth activity  
Compared to GFP-transduced control cells we detected a significant 1.9-fold increase in ATP 
activity of ZNF217-transduced hematopoietic C1498 cells. ZNF217 has been shown to 
function as a proto-oncogene in several cancers such as breast and ovarian carcinoma [156, 
188-190]. However, its role in normal or malignant hematopoiesis has never been 
addressed. To test the effect of ZNF217 overexpression on the viability of hematopoietic 
cells, we analyzed hematopoietic C1498 cells overexpressing ZNF217 by measuring their ATP 
activity level. Since ATP is an indicator of metabolically active and viable cells [126], this 
increase can be due to either more viable or more active cells.  
In addition to higher ATP activity level, our results indicated increased proliferation and 
growth potential in hematopoietic cells overexpressing ZNF217. To further test if ZNF217 
leads to a higher proliferation rate in hematopoietic cells, we examined the proliferation 
kinetics of ZNF217-transduced FDCP-Mix cells compared to GFP-transduced control cells. 
ZNF217 overexpressing cells showed a 1.4-fold increased proliferation 4 days after seeding in 
comparison to GFP-transduced control cells. This is in accordance with previous findings in 
non-hematopoietic cells showing that the proliferation ability of ovarian carcinoma ZNF217-
transfected cells was significantly higher than control cells [189, 191]. However, the detailed 
mechanism of ZNF217 on the proliferation of hematopoietic cells remains to be determined.   
 
5.3.2.2. Stable ZNF217 expression induces IL3 independency of FDCP-Mix and 32D 
cells  
We observed that 32D and FDCP-Mix hematopoietic cells which are highly interleukin 3 (IL3) 
dependent showed signs of transformation by acquiring the ability to become independent 
of IL3 when transduced with the LV encoding for ZNF217.  
The IL3 independency was examined and proved by performing two separate experiments 
on 32D and FDCP-Mix cells. Two weeks after plating 32D cells overexpressing ZNF217 in IL3-
free semi-solid medium, IL3-independent colonies were formed, whereas GFP-transduced 
control cells formed no colonies. The enrichment for ZNF217 overexpressing cells from 33%-
93% in the absence of IL3 indicated that only these cells could survive and proliferate 
without this cytokine. Hematopoietic 32D cells used in this experiment have previously 
served as a model cell system for studying the transforming properties of various leukemia-
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associated oncogenes such as Bcr/Abl [192, 193]. When 32D cells are cultured in the absence 
of IL3, they undergo cell cycle arrest and apoptosis [127]. 
Our findings were in accordance with Littlepage et al. results demonstrating ZNF217 
overexpression contributes to immortalization in both breast cancer cells and in vivo mouse 
transplant models [190]. We observed the same frequency of cytokine-independent cell 
colonies in ZNF217 compared to the positive control c-Myc, which is a known proto-
oncogene [128]. We conclude that ZNF217 overexpression might lead to transformation in 
hematopoietic cells.  
 
5.3.2.3. Expression profiling of ZNF217 overexpressing hematopoietic cells indicated 
deregulation of pathways involved in cellular movement 
Since ZNF217 has been described as a transcriptional regulator [157], we performed global 
gene expression profiling on ZNF217-transduced 32D hematopoietic cells to detect possible 
target genes and subsequently deregulated pathways. We observed that the number of 
downregulated genes was 4 times higher than upregulated genes in hematopoietic 32D cells 
overexpressing ZNF217 which confirms its previously known role as a transcription repressor 
[155, 157].  
We further observed that the networks deregulated in these cells are mainly involved in 
cellular movement. The role of ZNF217 in promoting epithelial-mesenchymal transition 
(EMT) in human mammary epithelial cells was previously shown [158, 190]. It was 
demonstrated that the frequency of increased ZNF217 copy number is higher in liver 
metastasis originated from colorectal cancer than in the primary colorectal tumors. None of 
the colorectal cancers which did not give rise to liver metastasis showed ZNF217 copy 
number amplifications [194]. However, in our gene expression profile cell movement 
networks affected by ZNF217 overexpression are downregulated. This might introduce the 
opposite effect of ZNF217 in hematopoietic cells.  
5.3.3. EVL overexpression increases cell viability and colony forming ability  
To assess the effect of EVL on hematopoietic cell viability and clonogenicity, hematopoietic 
C1498 cells transduced with the LV encoding for EVL were analyzed. We observed that in 
addition to higher ATP activity, EVL transduced C1498 cells formed more colonies compared 
to GFP transduced control cells in colony forming assay. So far, EVL has been reported to 
play roles in homologous recombination, DNA repair, actin remodeling and cell motility [168-
173].  
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To investigate whether the overexpression of EVL in hematopoietic cells led to deregulation 
of other genes and if these genes were involved in specific cellular pathways, global gene 
expression profiling of EVL overexpressing 32D cells was performed. We observed that EVL 
overexpression did not lead to any significant deregulation of the transcription of other 
genes. This can be due to the fact that EVL is not a transcription regulator molecule; 
therefore its overexpression does not affect up or downregulation of numerous genes at 
RNA level and might have post-transcriptional effects. 
5.3.4. Analyzing the effect of LRRC33 in vivo and in vitro  
5.3.4.1.           LRRC33 inhibits NF-kB activity through toll-like receptor 4  
LRRC33 is a member of LRR (Leucine-rich repeat) protein family and subgrouped in 
LRR_Tollkin (clustering with the Toll proteins) [195]. Its protein structure is similar to toll-like 
receptor (TLR) proteins [129, 130]. Therefore, we tested whether LRRC33 can function as a 
TLR co-receptor and affect NF-kB activity when the cells were stimulated with 
lipopolysaccharides (LPS). We observed that LRRC33 decreased NF-kB activity via TLR4. 293T 
cells transfected with TLR4 and murine LRRC33 showed reduced level of NF-kB activity 
compared to cells transfected with TLR4 and GFP after LPS stimulation. Our data on murine 
LRRC33 suggested the same reported inhibitory effect of human LRRC33 indicating that this 
protein might have an effect on reducing pro-inflammatory signals [130], which can be one 
of the proposed roles for LRRC33 in innate immunity according to its protein structure.  
NF-κB has been shown to be active in various immune cells as well as non-hematopoietic 
cells and to function as a critical player in coordinating inflammation and immune cell 
functions [196]. However, the role of NF-κB in HSC has not been profoundly explored. It was 
shown that the function of microRNA 146a, which downregulates NF-kB, is necessary for 
maintaining HSC homeostasis and longevity under steady state conditions in murine 
hematopoietic system. This implies that NF-kB inhibition might be important in maintenance 
of HSC pool and homeostasis of blood cells [197, 198]. Therefore further analyses of LRRC33 
role under stressed and steady state conditions can clarify how LRRC33 functions in 
hematopoiesis regulation. 
5.3.4.2. LRRC33 influences macrophage and T-cell differentiation in vivo 
In order to study the effect of the selected genes on long term multilineage reconstitution 
and self-renewal of LSK cells in vivo, we transduced LSK cells with the LV of LRRC33 and 
transplanted the cells into recipient mice. Analyzing the role of LRRC33 in vivo, we observed 
that LRRC33-overexpressing LSK cells show higher differentiation towards macrophages and 
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lower differentiation towards T-cells compared to control-transduced cells in a small cohort 
of 10 recipient mice. Since it was shown that NF-kB pathway plays roles in myeloid or 
lymphoid lineage development [199, 200] and considering our previous finding of LRRC33 
inhibitory role on NF-kB activity in vitro, we conclude that this difference in T-cell and 
macrophage differentiation might be due to the changes in NF-kB activity.  
The role of NF-kB family members in different stages of T-cell development was 
subsequently evaluated in detail using several transgenic mouse models for different 
members of NF-kB protein family. For instance, knocking out one of the NF-kB protein family 
members, RelB, inhibits T-cells development to CD4-CD8+ cells in peripheral blood [199]. 
Therefore, performing further in vitro analyses to study the effect of LRRC33 on 
hematopoietic cell differentiation towards myeloid and lymphoid lineages is suggested. In 
addition, LRRC33- transduced LSK cells should be transplanted into larger number of 
recipient mice to further validate the detected lineage bias.  
5.3.5. Analyzing PLCB4 function in vitro and in vivo using PLCB4 knockout mice  
The role of PLCB4 in hematopoietic system has been never profoundly investigated. 
Analyzing RNA expression level of PLCB4 revealed its higher expression in HSC and MPP1 
populations. In this study we used PLCB4 knockout mice to determine the role of PLCB4 in 
hematopoiesis. Moreover, since the coding sequence of PLCB4 gene is large (3.5 kb), 
producing LV of PLCB4 at high titer was challenging and studying its overexpression effect on 
hematopoietic cells could not be achieved efficiently.  
5.3.5.1. Eighteen-day old PLCB4 knockout mice show decreased level of LSK cell 
count   
Analyzing PLCB4 knockout mice [201], we observed that breeding +/- mice led to 11% of 21-
day old -/- progenies which was 14% less than expected mendelian ratio. Moreover, the -/- 
mice are clearly smaller than +/- or +/+ mice and show retarded body growth. Since we 
could not detect a significant difference in the death rate of newborn and younger than 21-
day old pups, and the newborn -/- pups have lower body weight, we conclude that there was 
a significantly higher death rate of fetuses before birth. Therefore, genotyping fetuses will 
clarify the death of -/- PLCB4 mice at embryonic stages. Since we previously observed signs 
of hematopoietic abnormalities in mice at young ages, we can further study if hematopoietic 
deficiencies are involved in the death of mice before birth.  
The function of Phopholipase C beta4 has been well studied in central nervous system [202, 
203]. Nuclear PLCB1, another member of phospholipase proteins, has been shown to play an 
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important role in controlling the balance between cell cycle progression and apoptosis in 
hematopoietic myelodysplastic syndrome cells [204]. Okada et al. performed a genome-wide 
single nucleotide polymorphism (SNP) analysis on patients with various diseases such as 
different types of cancers and myocardial infarction. In their study the subjects who were 
homozygous for neutrophil-increasing alleles in both of the SNPs had 1.17-fold higher 
neutrophil counts when compared with the subjects homozygous for neutrophil-decreasing 
alleles. They demonstrated that PLCB4 locus is significantly associated with the regulation of 
neutrophil count [205]. 
We observed that BM cells from 18-day old mice contained 2-fold less LSK cells compared to 
40-day old mice. Moreover, a 2-fold decrease in the number of preB-cell colonies was 
detected in the BM cells from -/- vs. +/- , and -/- vs. +/+ 18 and 25-day old mice compared to 
preB-cell colony count in 40-day old mice. Since preB-cell colony forming cell (CFC) assay was 
performed with the whole BM cells, which we showed contain less LSK cells, the reduction 
observed in pre-B colonies could be explained by lower number of LSK cells which are 
responsible for giving rise to pre-B cells. Unlike preB-cell CFC assay, myeloid colonies 
detected in myeloid CFC did not exhibit any significant differences in the number and type of 
various myeloid colonies in -/-, +/- and +/+ PLCB4 mice, however myeloid colony forming 
potential in younger mice and fetuses are still to be investigated.  
These results strongly suggest examining the hematopoiesis in the BM of newborn and 
younger than 18 day-old mice. Since the process of HSC development during embryogenesis 
engages various anatomical sites such as yolk sac, placenta, and fetal liver [206-208], 
analyzing hematopoietic system of PLCB4 knockout mice at early embryonic stages can 
elucidate the role of PLCB4 protein in various hematopoietic developmental stages.  
In addition to ex vivo assays, BM cells from 40 day-old -/-, +/- and +/+ PLCB4 mice were 
transplanted into irradiated recipients to evaluate multilineage engraftment and self-
renewal during serial transplantation. No significant difference in long term multilineage 
reconstitution was observed in the primary recipients 6 months after BMT, however 
secondary and tertiary recipient mice are still to be evaluated to study the self-renewal 
ability of BM cells derived from PLCB4 KO mice. It was demonstrated that BM from young 
mice has different potential in multilineage reconstitution compared to older mice [209, 
210]. For instance, older mice BM have been shown to contain more HSC by measuring their 
competitive repopulating ability in vivo [211]. However, according to our in vitro analyses, 
18-day old -/- mice contain less HSC compared to 40-day old mice which can be due to the 
effect of PLCB4 candidate gene. Therefore, performing limiting dilution in competitive 
repopulating assays in young and old mice can clarify the role of PLCB4 in long-term 
repopulation and multilineage reconstitution in hematopoiesis. 
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In summary, the BM from PLCB4 KO mice was shown to contain less LSK cells compared to 
wild type mice. Since this difference could be only detected in 18-day old mice and not older 
mice, analyzing the hematopoietic system in adult mice at young ages and murine embryos 
will unravel the role of PLCB4 in hematopoiesis.  
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Conclusion  
In this study we demonstrated that clinical integration site datasets from gene therapy 
patients can be used to identify regulatory genes of hematopoiesis. We developed a strategy 
to select hematopoietic candidate regulatory genes by analyzing the genome wide IS 
repertoire from 10 WAS gene therapy patients. Following the selection of various candidate 
genes, we examined whether these genes play a role in the regulation of hematopoiesis. 
Performing various in vitro and in vivo analyses to address proliferation, differentiation and 
self-renewal, we demonstrated that four out of five candidate genes have an influence on 
hematopoietic primary cells. This clearly validates the established selection strategy and 
proves its significance. The identified genes will be further evaluated for their hematopoietic 
stem cell regulatory potential on molecular level. We could clearly show that this strategy 
can be applied for protein-coding genes and we aim to extend the identification of novel 
non-coding regulators in future. The systematic identification of novel hematopoietic 
regulatory genes in meta-datasets derived from a large number of gene therapy studies and 
subsequent in vitro and in vivo validation will allow gaining new insights into the biology of 
post-embryonic hematopoiesis. 
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